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This thesis is arranged in three parts; Part 1  is the review paper and this includes 
a background to liver disease including prevalence, possible causes and the different 
stages with regards to clinical presentations. It provides an outline of some of the major 
complications of liver disease, including hepatic encephalopathy. A discussion of 
minimal hepatic encephalopathy follows, which includes a review of the literature on 
cognitive deficits. Possible causes are identified with implications for future research 
discussed.
Part 2 consists of the empirical paper: an introduction to the research presented in 
this thesis and the specific aims and hypotheses investigated. The methodology of the 
study follows which provides information about participants (patients with varying 
stages of liver disease) and controls. The neuropsychological tests are listed and the 
different cognitive domains they measure outlined. The results section presents all the 
major findings from the current research with a summary of how they tie in with the 
hypotheses. Further elaboration of the findings is given in the discussion, which also 
considers how the results tie in with previous studies.
Part 3 of the thesis consists of a critical appraisal of the research. It is organised 
in two parts: the first section is a personal reflection of the research process and 
discusses some of the personal experiences encountered during the study. The second 
section elaborates on the discussion from Part 2 and includes a consideration of research 
and clinical implication that have emerged from the study. An acknowledgment of the 
study’s various strengths and limitations is included in this section.Table of Contents
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1Abstract
The following review discusses some of the cognitive and functional 
problems in liver disease. Some medical literature is included which is consistent 
with difficulties reported by patients. Prevalence, possible causes, and types of liver 
disease are reviewed, including an outline of various complications associated with 
the disease.  Hepatic encephalopathy (HE) is one such complication and a general 
background to this is given.
It has been suggested that subgroups of patients with liver disease have mild 
cognitive deficits and demonstrate poorer performances on neuropsychological tests 
compared with matched controls. This has been termed minimal hepatic 
encephalopathy (MHE), a syndrome that occurs in patients with liver disease without 
overt symptoms of hepatic encephalopathy. The full spectrum of cognitive 
impairment in MHE is unknown (Collie, 2005).
Research has attempted to understand the profile of cognitive deficits in 
patients with liver disease. Studies have investigated various areas of functioning 
(e.g. psychomotor skills, attention and memory) by neuropsychological testing. The 
main studies are presented in the review. Some of the limitations of the minimal 
hepatic encephalopathy hypothesis are discussed. There is some debate about 
possible causes of observed cognitive deficits and various psychological models 
including health (coping and quality of life) and clinical (mood issues) are proposed. 
Further research and clinical implications are also discussed.
2Introduction
1.1  Background
The prevalence of liver disease in the United Kingdom is increasing and this 
has important medical, occupational, social and psychological implications. Previous 
research has shown that liver disease patients do significantly worse in psychometric 
tests when compared to healthy controls (Elithom, Lunzer & Weinman, 1975; 
Hegedus, Tarter, Van Thiel, Schade, Gavaler& Starzl, 1984; McCrea, Cordoba, 
Vessey, Blei & Randolph, 1996). Patients also report reduced quality of life (Forton, 
Thomas, Murphy, Allsop, Foster, Main, Wesnes, Taylor-Robinson, 2003) and work- 
related activities (Hamster, 1982).
The term minimal hepatic encephalopathy (MHE) has been used to describe a 
subgroup of liver disease patients who are characterised by ‘normal’ mental status. 
This is defined by the patient’s presentation in clinical practice, (e.g. a presence of 
effective communication, engagement, coherent speech, and an absence of noticeable 
cognitive disturbances, as outlined in Table 2). The medical consultant involved in 
the patient’s care assesses this. However, patients often report subtle cognitive 
dysfunction and problems performing everyday tasks. Such cognitive deficits are 
evident upon neuropsychological testing (Ferenci, Lockwood, Mullen, Tarter, 
Weissenbom & Blei, 1998; Gitlin, Lewis & Hinkley, 1986). Altered cerebral 
functioning has also been observed (Schomerus, Hamster, Blunck, Reinhard, Mayer 
& Dolle, 1981).
Minimal hepatic encephalopathy is believed to be a mild form of hepatic 
encephalopathy (HE). This is understood as a “clinical picture that can present when 
damage to the brain and nervous system has occurred as a complication of liver 
disorders” (Pantiga, Rodrigo, Cuesta, Lopez & Arias, 2001). It has not been
3attributed to any one cause or mechanism/toxic substance but is believed to stem 
from the combined effect of several factors (Pantiga et al, 2001). A role for advanced 
ammonia levels in HE has also been identified which has been used to account for 
the cognitive deficits observed (Blei & Cordoba, 2001). However, the full extent of 
impairment and their exact cause is unknown and few studies have investigated 
psychological factors and prevalence of mood (e.g. anxiety and depression) in 
patients with liver disease.
1.2  Liver Disease and Lifestyle
The term iiver disease’ applies to many diseases and disorders that cause the 
liver to function improperly or stop functioning (Stone, 2004). Hospital statistics 
show deaths from liver disease are increasing in the United Kingdom and deaths 
from alcoholic liver disease have doubled in the last 10 years. The British Liver Trust 
(2007) has warned that the prevalence of liver disease in the United Kingdom is 
likely to increase dramatically over the coming years as unhealthy lifestyles take 
their toll. This has serious psychological implications relating to cognitive 
complaints, reduced quality of life and work-related activities and mental health 
problems.
Almost half of all clinical presentations of liver disease are alcohol related. 
The Alcohol Harm Reduction Project (2003) showed how ‘binge drinking’ accounts 
for 40% of all drinking occasions among men and 22% by women in the United 
Kingdom. Alcohol Concern (2003) have defined binge drinking as consuming over 
half the government’s recommended number of units for a week in one session, i.e. 
ten units for men and seven units for women (Raistrick, 1999).
Studies have suggested that binge drinking is most characteristic of the 
young. The General Household Survey (2002) found that those aged 16-24 are more
4likely to binge-drink, with 36% of men and 27% of women reporting binge-drinking 
at least once a week.  There is further concern about the drinking behaviour of 
children and adolescents. Plant, Miller and Plant (2004) looked at trends in drinking 
and illicit drug use among a sample of2032 United Kingdom school students aged 
15-16 years in a cross sectional survey. Findings were compared with earlier surveys 
conducted in 1995 and 1999. Results showed that over 90% of respondents had 
consumed alcohol at some time and 75% had been ‘drunk’. This was an increase 
compared with the two previous studies.
Binge drinking is also estimated to cost the country £20 billion a year, 
according to a recent government report. The study by the Prime Minister’s Strategy 
Unit (2003) shows 17 million working days are lost to hangovers and drink related 
illness each year. Billions more are thought to be spent clearing up alcohol-related 
crime and social problems and there are 1.2 million incidents of alcohol-related 
violence each year. The study also shows parents with drink problems affect 1.3 
million children. This can lead to a range of adverse long-term effects, affecting 
general development and adjustment.
Obesity is another risk factor for liver disease. In societies where inactive 
lifestyles are led and high calorie diets with excessive amounts of fat and sugar are 
consumed, problems for the future in terms of health and obesity follow. The British 
Cardiovascular Society (2007) warns that the prevalence of liver disease will also 
subsequently increase. Non-alcoholic fatty liver disease is observed primarily in 
developed societies and is the most common form of liver disease in the United 
States and world-wide, affecting an estimated 10-24% of the world population and 
this figure is also set to increase.
51.3  Types of Liver disease
The liver is considered the most important organ of the body after the heart, 
being essential for healthy body functioning. It is also the largest organ and performs 
a number of essential functions. For example, it neutralises germs and bacteria from 
the blood and produces immune agents to control infection; the liver also makes 
proteins that regulate blood clotting.
As proposed by Richardson (2002) the simplest classification of liver disease 
is acute and chronic. The definition of acute liver disease (such as acute hepatitis and 
acute liver failure -  ALF) is based on duration, with the history of the disease not 
exceeding six months. Diseases of longer duration are classified as chronic (such as 
chronic viral hepatitis, cirrhosis). Cirrhosis of the liver is an important cause of 
illness and death, hi 2000 it killed more men than Parkinson’s disease and more 
woman than cancer of the cervix (Donaldson, 2001).
Donaldson (2001) further outlined how large rises in death rates from chronic 
liver disease and cirrhosis have occurred in most age groups. In 45-54 year olds, 
there has been a greater than fourfold increase amongst men since the early 1970’s 
and a threefold increase in woman. In 35-44 year olds, the rise has been even larger: 
an eightfold increase in men and approaching a sevenfold increase in women.  The 
rise of deaths from cirrhosis amongst younger people is of particular concern where 
binge-drinking patterns appear to be common. In 2000 cirrhosis accounted for nearly 
500 deaths in men aged 25-44 years and nearly 300 deaths in women of this age 
group (Donaldson, 2001).
Both acute and chronic definitions of liver disease involve damage to the 
liver. Infection, injury, exposure to drugs or toxic compounds, an autoimmune 
process or genetic causes could cause this. The disease can also be categorised by the
6effect it has on the liver. Hepatitis is an inflammation of the liver, cirrhosis involves 
scarring and progressive cell death, stones cause blockages, fatty liver and cancer are 
relatively rare but can be life threatening.
1.3.1 Hepatitis
There are two major forms of hepatitis: One in which the liver is damaged 
quickly and one in which the liver is damaged slowly, over a long period of time. 
These viruses have been named in the order of their discovery as Hepatitis A, B, C, 
DandE.
•  Hepatitis A is spread through infected water and food and is 
especially common in children. Most infected people are not aware they have 
been exposed to the virus.
•  Hepatitis B is fairly common, especially in Asia and Africa.  It is still
the most common cause of acute viral hepatitis in North America and Europe. 
Hepatitis B can be spread by exposure to blood, through sexual relations and 
from mother to baby.
•  Hepatitis C is passed the same way as  hepatitis B. Hepatitis C is less
common than B, but the majority of the people who contract it become 
chronically infected, able to spread the infection to others and usually have 
chronic damage to the liver.
•  Hepatitis D and E are relatively rare.
1.3.2 Cirrhosis
As outlined by the British Liver Trust (2007) cirrhosis can be understood as 
the medical term to describe excessive development of scar tissue (fibrosis) within 
the liver.  When the liver is acutely damaged, some of the liver cells die and the 
organ regenerates itself. If, however, a chronic disease process damages the liver,
7scarring develops. In cirrhosis of the liver, scar tissue replaces normal, healthy tissue, 
blocking the flow of blood through the organ and preventing it from functioning 
normally. In the initial stages, this process is relatively slow and progresses over 
many years without causing any symptoms. However, eventually excess scar tissue 
builds up and this begins to interfere with some of the vital functions of the liver and 
at this stage, it is no longer able to regenerate itself.
A number of conditions can lead to cirrhosis (The National Digestive 
Diseases Information Clearing House, 2003). The common causes include excessive 
alcohol intake, chronic hepatitis C virus infection, Non-alcoholic fatty liver disease, 
autoimmune chronic active hepatitis, primary biliary cirrhosis, chronic hepatitis B 
virus infection, inherited diseases such as Wilson’s disease, Glycogen/lipid storage 
diseases, prolonged exposure to some drugs or toxins and diseases of blood vessels.
1.3.3 Gallstones
Cholesterol in the bile pigments (bilirubin) in the bile may form stones in the 
gallbladder.  These stones may or may not cause symptoms and problems, depending 
on their size and location.  If present over long periods, they may damage the gall 
bladder and this often causes a feeling of bloating and discomfort in the upper 
abdomen after meals, especially ones high in fat.
1.3.4 Obstruction
Gallstones, tumours, trauma and inflammation can cause blockages or 
obstructions in the bile ducts (which drain the liver). When an obstruction occurs, 
bile and its related wastes accumulate in the blood and the patients skin and eyes 
often turn yellow (jaundice).  Obstructions may be chronic and cause few symptoms, 
but they can also be acute and even life threatening.
81.3 .5 Fatty Liver
Fatty liver causes liver enlargement and abnormal liver function. The most 
common cause is excessive alcohol consumption. It is usually a reversible condition, 
resolving with abstention from alcohol. While symptoms are usually fairly mild, it 
may cause cirrhosis and it is seen most commonly in overweight and diabetic 
individuals.
1.3.6  Liver cancer
Hepatitis and cirrhosis may lead to liver cancer in some cases, but cancer 
from other parts of the body that spreads to the liver is more common. People who 
have chronic hepatitis or cirrhosis may be checked on a regular basis for cancer.
1.4 Genetic causes of liver disease
The most common genetic liver disorder is called Haemochromatosis. It 
involves an excess of iron and is most common in adults.  There are numerous 
genetic liver diseases that affect children.
1.5  Signs and Symptoms
Liver disease is often discovered during routine testing. It may not cause any 
symptoms at first or these may be very subtle, such as loss of energy. Chronic liver 
disease symptoms include jaundice, dark urine and abdominal swelling due to the 
accumulation of fluid, itching, unexplained weight loss or gain, and abdominal pain; 
symptoms may not be present until the disease has reached an advanced stage. 
Treatment is directed at managing the complications of cirrhosis and preventing 
further damage to the liver.
91.6 Other Health Complications
A weak liver can be the cause of many other chronic health problems, 
including gallbladder problems, constant fatigue, sleep disorders, heart palpitations, 
skin problems, allergies, arthritis, thyroid problems and frequent fainting. In addition 
woman’s health problems such as uterine fibroids, ovarian cysts, breast cysts, 
endometriosis and painful menstruation may also be the result of a weak liver.
Additionally, as outlined above, abdominal pain has been associated with 
liver disease/hepatitis. Palmer (2004) outlines how patients often experience 
abdominal pain or discomfort around the area of the liver. The precise cause of this is 
unknown and some medical health professionals do not attribute the pain to the 
actual liver itself but to other causes  (i.e. pancreatitis, gallstones or inflammation).
1.7 Prognosis of liver disease
The Child Pugh (CP) or Child Turcotte Pugh Score (Child & Turcotte, 1964; 
Pugh, Murray-Lyon, Dawson, Pietroni & Williams, 1973) is used to assess prognosis 
of chronic liver disease, mainly cirrhosis. It was initially used to predict mortality 
during surgery but is now used to determine the prognosis, treatment and the 
necessity of liver transplantation.
Child Pugh scores are also used to assess severity/stage of liver disease, with 
Child Pugh stage C considered more severe than Child Pugh stage A (Collie, 2005; 
Ortiz, 2005).  The assessment employs 5 clinical measures of liver disease: bilirubin, 
semm albumin, INR, Astrocyte function and hepatic encephalopathy. Together, these 
are used to calculate the number of points that determines the CP score.
10This is illustrated in Table 1:
Points CP 1  year survival 2 year survival
5-6 A 100% 85%
7-9 B 81% 57%
10-5 C 45% 35%
Table 1: Prognosis of liver disease CP = Child Pugh Score
1.8  Hepatic Encephalopathy
As outlined above, chronic liver disease results in cirrhosis and scarring of 
the liver/liver dysfunction.  This is often associated with many complications, 
including accumulation of fluid in the abdomen, bleeding disorders, increased 
pressure in the blood levels of the liver (portal hypertension) and a confusion or 
change in the level of consciousness. The latter is known as hepatic encephalopathy 
(HE). This is a complex neuropsychiatric condition that occurs as a consequence of 
acute or chronic liver disease (Rose & Jalan, 2005).
As documented by Summerskill, Davidson, Sherlock & Steiner (1956), the 
different neuropsychological features of hepatic encephalopathy were described 
centuries ago when Hippocrates stated that “those who are mad on account of 
phlegm are quiet, but those on account of bile are vociferous, vicious, and do not 
keep quiet”. A number of authors have assumed that Hippocrates was describing 
patients with acute liver injury and that his illustrations reflect the presentation of 
such patients.
Today, hepatic encephalopathy is understood as a “clinical picture that can 
present when damage to the brain and nervous system has occurred as a complication 
of liver disorders” (Pantiga, Rodrigo, Cuesta, Lopez & Arias, 2001). It is believed to
11be associated with a variety of overt neuropsychiatric manifestations including 
personality disorders, inappropriate affective, behavioural and sleep disturbances and 
cognitive and psychomotor impairments (Mattarozzi, Stracciari, Vignatelli,
D’ Alessandro, Morelli & Guarino, 2005).  Other signs can include flapping tremor 
(asterixis) and a decreased level of consciousness.
Wolfe (2007) proposes subtle signs of hepatic encephalopathy are observed 
in nearly 70% of patients with cirrhosis and that symptoms may be debilitating in a 
significant number of patients. Approximately 30% of patients dying of end-stage 
liver disease experience significant encephalopathy, approaching coma (Wolfe,
2007)
1.8  .1 Grading of Hepatic Encephalopathy
Hepatic encephalopathy is graded according to four stages of severity.  Early 
features include reversal of sleep patterns, apathy, hypersomnia, irritability and 
personal neglect. In later stages, delirium and coma may occur. Worobetz (2007) 
outlined the following features associated with each stage of severity in hepatic 
encephalopathy -  Table 2.
12Grade  Level of
Consciousness
Intellectual  Neurological  EEG
Function  findings
1  Lack of awareness;  Short
Personality change;  attention 
Day/night reversal
Incoordination  Slowing
2  Lethargic;
Inappropriate
Behaviour
disorientated  Asterixis;  Slowing 
abnormal 
reflexes
3  Asleep;
Rousable
Loss of  Asterixis;  Slowing
meaningful  Abnormal
Commun-  reflex
ication
4  Unrousable Absent Decerebrate  Very slow
Table 2. Grades of Hepatic Encephalopathy - (Worobetz. 2007)
Additionally, the evaluation of severity of persistent hepatic encephalopathy 
is based on the West Haven Criteria for semi-quantitative grading of mental status, 
referring to the level of impairment of autonomy, changes in consciousness, 
intellectual function, behaviour and the dependence of therapy (Ferenci, Lockwood, 
Mullen, Tarter, Weisenbom & Blei, 1998).  Worobetz (2007) and Ferenci et al 
therefore present separate grading systems of hepatic encephalopathy.
1.8.2  Aetiology
The precise aetiology of hepatic encephalopathy is unknown. It is not 
attributed to any one cause/mechanism or toxic substance, rather from the combined 
effect of several factors (Jones, 2000).  There is no specific biochemical test for 
hepatic encephalopathy.
A number of theories have attempted to explain the development of hepatic 
encephalopathy in patients with cirrhosis. Some investigators contend that hepatic 
encephalopathy is a disorder of astrocyte (supporting brain cells) function. They play
13an important role in the detoxification of a number of chemicals (Wolf, 2007) and 
alterations may prevent them from functioning normally.
Ammonia is usually converted to urea by the liver. Additionally ammonia is 
one chemical detoxified by astrocytes.  Two factors have led to the ‘ammonia 
hypothesis’ of hepatic encephalopathy (Blei & Cordoba, 2001): first, there is a 
decreased amount of functioning astrocytes, resulting in fewer opportunities for 
ammonia to be detoxified. Secondly, portosystemic shunting may divert blood 
containing ammonia from the liver to the wider circulation of the body. Additional 
support for the ammonia hypothesis comes from the clinical observation that 
treatments that decrease blood ammonia levels can improve hepatic encephalopathy 
symptoms.
One argument against the ammonia hypothesis, however, is the observation 
that approximately 10% of patients with significant encephalopathy have normal 
serum ammonia levels. Furthermore, many patients with cirrhosis have elevated 
ammonia levels without evidence for encephalopathy (Wolf, 2007).
Another hypothesis has identified the neurotransmitter Gamma-aminobutyric 
acid (GABA). GABA is a neuroinhibitory substance and for 20 years, it was 
postulated that hepatic encephalopathy was the result of increased GAB Aergic tone 
in the brain.
1.9  Minimal Hepatic Encephalopathy
Collie (2005) and Weissenbom (1999) proposed that a mild form of hepatic 
encephalopathy is termed sub-clinical hepatic encephalopathy (SHE) or minimal 
encephalopathy (MHE). This syndrome is found in cirrhosis, yet to date it is not well 
understood. It is often characterised by ‘normal’ mental presentation (Rose & Jalan,
142004). A medical consultant involved in the patient’s care assesses this at the time of 
clinical presentation. It is often defined as a presence of fluid and coherent speech, 
appropriate engagement and an absence of cognitive deficits (poor attention, 
concentration) or symptoms typically found in hepatic encephalopathy (Table 2).
Some confusion is associated with this definition. Despite ‘normal’ 
presentations, such patients can report experiencing subtle cognitive complaints, 
which can make it difficult for them to perform daily activities (Groeneweg, Quero, 
De Brujin, Hartmann, Essinck-Bot, Hop & Schalm, 1998). Often, these are not 
reported unless the patient is asked. Such patients have also demonstrated cognitive 
dysfunction evident upon neuropsychological testing (Collie, 2005; McCrea, 
Cordoba, Vessey, Blei & Randolph, 1996).  This has been attributed to altered 
cerebral functioning (Schomerus, Hamster, Blunck, Reinhard, Mayer & Dolle, 1981).
Recent studies have suggested that minimal hepatic encephalopathy may be 
distinguished functionally from other clinical forms of hepatic encephalopathy, i .e. 
episodic and persistent encephalopathy, primarily by the absence of overt 
neurological symptoms, such as asterixis, flapping tremor and pronounced 
fluctuations of vigilance (Weissenbom, Ennen, Schmerus, Ruckert & Hecker, 2001). 
Traditionally the diagnosis has been limited to patients with cirrhosis of the liver.
1.9.1  Prevalence
There is a degree of confusion over the prevalence of minimal hepatic 
encephalopathy in cirrhotic patients. The diagnostic criterion is poorly understood 
and there is a lack of consensus on how it is detected, with some speculation over the 
relevance of the syndrome by some clinicians (Collie, 2005). Patients are typically 
diagnosed with minimal hepatic encephalopathy by the consultant involved in their 
care when they do not present clinically with overt signs of hepatic encephalopathy
15(Table 2) but report mild cognitive deficits and complain of reduced abilities to 
perform daily tasks.
In clinical practice, there is no uniformly accepted diagnostic criterion for 
minimal hepatic encephalopathy. Tests used to establish a diagnosis typically include 
the psychometric hepatic encephalopathy score (PHES) for screening purposes. This 
test assesses attention and psychomotor function and consists of five paper-pencil 
tests that are scored by comparison with data of healthy controls. However, this test 
is not widely used and the initial enthusiasm with it has subsided, mainly due to 
criticisms of it being rather limited. For example, various components of attention 
and information processing considered necessary for driving/reduced risk of 
accidents are not directly measured. Other test batteries have been proposed which 
examine motor speed and accuracy, visual perception, visuo-spatial orientation, 
visual construction, concentration, attention and to a lesser extent, memory (Collie,
2005).
Some clinicians base diagnosis on the result of the psychometric hepatic 
encephalopathy score test alone (Gitlin, Lewis & Hinkley, 1986) while others 
consider results of neurophysical and neuropsychological testing together (Saxena, 
Bhatia & Joshi, 2001). Collie (2005) also outlines how there is often no clear 
rationale for the use of particular tests used to diagnose MHE and several studies 
have employed neuropsychological test batteries assessing a limited number of 
cognitive domains, such as attention and motor skills  (McCrea, Cordoba & Vessey, 
1996).
The prevalence of minimal hepatic encephalopathy can also be understood in 
terms of Child Pugh score. It is generally accepted that among patients with a Child 
Pugh stage A, better liver function is likely and few cognitive complaints are
16reported. However, in patients with a Child Pugh score of B or C, (indicating more 
advanced cirrhosis), MHE is probably likely in approximately 50 % of them 
(Groeneweg, Moerland, Quero, Hop, Krabbe & Schalm, 2000).
Depending on the test or definition used, the prevalence of minimal hepatic 
encephalopathy has been shown to vary between 30-84% in cirrhotic patients 
(Groeneweg et al, 1998). For example, Saxena, Bhatia & Joshi (2001) required that 
some impairment be observed on any one of four outcome measures, while Das, 
Dhiman & Saraswat (2001) required that performance be impaired on at least two of 
nine psychological tests. Subsequently, inconsistencies in the diagnostic criteria and 
methods between studies have contributed to wide variations in the reported 
prevalence of cognitive dysfunction in liver disease. Hilsabeck, Perry & Hassanein
(2003)  found that the rate of cognitive dysfunction varied between 0% and 82% 
depending upon the neuropsychological tests used to identify impairment. This is 
also the view of Rikkers, Jenko & Rudman (1978).
It is believed that minimal hepatic encephalopathy probably predisposes 
individuals to hepatic encephalopathy. Cirrhotic patients with MHE more frequently 
develop episodes of overt encephalopathy than those without MHE. In one study, the 
probability of overt encephalopathy at 3 years was 56% for those with a diagnosis of 
MHE and 8% for those without MHE (Oritz, 2005). Mild cognitive dysfunction can 
be considered a precursor to overt HE, the development of which carries a poor 
prognosis, with survival 1  -year post diagnosis of approximately 40% (Bustamante, 
Rimola & Ventura, 1999). Therefore, identification and treatment of individuals at 
risk for conversion to hepatic encephalopathy is important in preventing death among 
cirrhotic patients. As described in current best practice guidelines (Blei & Cordoba, 
2001), there are a number of treatment options for patients with overt HE, including
17dietary management, reduction of nitrogenous load from the gut, and administration 
of drugs that affect neurotransmission.
1.10  Neuropsychological functioning in Liver Disease
A number of studies have investigated performances on neuropsychological 
tests between liver disease patients and controls.  Most studies have excluded 
patients with overt signs (e.g. tremor, psychomotor dysfunction, impaired memory) 
of hepatic encephalopathy. These are presented in Table 3.
18Researcher Sample Size (N) Area of
functioning
studied
Findings
Weissenbom 
Et al. (2003)
45 early HE 
patients and 52 
controls
Memory Patients scored 
lower than 
controls in 
memory tasks
Mechtcheriakov 
et al. (2004)
14 cirrhotic 
patients and 22 
controls
Visuo-motor 
function; visuo- 
constructive 
ability;
Frontal areas; 
Memory; 
Verbal IQ
Significant 
deficits in visuo- 
motor function, 
visuo- 
constructive 
ability and 
frontal tasks.
Pantiga et al 
(2001)
89 cirrhosis 
patients; 31 
controls
Memory + 
immediate 
attention/recall; 
Visual-motor 
processing + 
mental flexibility; 
General reasoning 
and non-verbal IQ
Cirrhotic patients 
showed a degree 
of mental 
impairment in all 
functions studied
Mattorozzi et al 
(2004)
23 cirrhotic 
patients and 23 
controls
Attention, memory 
& language
Significant 
differences in 
attention and 
memory tasks
Gilberstadt et al 
(1980)
20 cirrhotic 
patients and 11 
controls
Motor
performance
Significant 
differences in 
motor
performance
Tarter et al 
(1984)
17 cirrhotic 
patients and 15 
controls
Visual perception; 
visual orientation; 
visuoconstuction; 
attention
Significant 
deficits in all 
cognitive areas
Table 3: Cognitive functioning in early stage liver disease patients and controls 
1.10.1 Summary of Findings
The most consistent findings have shown attention deficits and psychomotor 
deteriorations in minimal hepatic encephalopathy. Mattarozzi, Stracciari, Vignatelli,
19D’ Alessandro, Morelli & Guarino (2004) found patients had significant deficits on 
tests of visuospatial, selective and sustained attention. Visuospatial attention was 
examined by Visual Matrices, Cross Out a Test and Trail Making Test (TMT) A and 
B; selective attention was assessed by the Stroop colour test.
Additionally, Pantiga, Rodrigo, Cuesta, Lopez & Arias (2001) assessed 
cognitive deficits in patients with different stages of hepatic cirrhosis and found 
significant differences on tests of visual motor processing and motor flexibility. 
Pantiga et al argued the severity of deficit was related to the degree of hepatic 
dysfunction. This study is one of the most important to consider given the 
comprehensive test battery used and the classifications of severity of liver disease 
acknowledged.
Another important study to consider is the one by Mechtcheriakov, Graziadei, 
Mattedi, Bodner, Kugener, Hinteihuber, Marksteiner and Vogel (2004). This study 
also investigated visual-motor deficits in patients with liver cirrhosis and found 
significant deficits in visual-motor function, visual-constructive ability and verbal 
fluency in patients with cirrhosis as compared with an age-matched control group. 
Other neuropsychological functions such as short and long term memory (measured 
by the Rey Osterreith Complex Figure test) as well as verbal intelligence did not 
differ significantly between patients and controls.  Like the work by Pantiga et al
(2004), this study assessed a fairly wide range of cognitive skills and verbal IQ.
The studies suggest that whilst motor deficits are observed in cirrhotic 
patients, memory functioning is less well understood. Mattarozzi et al (2004) found 
patients had deficits on tests of visuospatial short term memory compared with 
controls and Weissenbom, Heidenreich, Giewekemeyer, Ruckert & Hecker (2003) 
investigated whether defective memory is a feature of early hepatic encephalopathy.
20They found that patients scored lower than the controls in all most tests applied 
(except one of spatial memory - the Rey Osterreith Complex Figure test). They 
concluded that patients scored lower in memory tasks predominantly because of 
deficits in attention and visual perception.  To date, the existing data on memory 
function in cirrhotics are sparse and most tests applied so far have been recall tests as 
opposed to tests of recognition.
Research into cognitive deficits in liver disease patients can help establish 
specific ‘patterns’ of cognitive deficits, in order to inform development of test 
batteries for diagnosis of minimal hepatic encephalopathy (Oritz, 2005). For 
example, in addition to the above studies, McCrea, Cordoba, Vessey, Blei & 
Randolph (1996) observed a relatively selective dysfunction of attention and motor 
speed in cirrhotics, in the absence of impairments in general intellect, memory, 
language or visuo-spatial skills.
Although all of the studies above reported using patients with early stage 
liver disease, not all explicitly reported how this was defined or whether they had 
excluded patients with overt features of hepatic encephalopathy. Patients with more 
severe cases of liver disease may have been included, therefore. Most of the studies 
used patients with different types of liver disease and Child Pugh scores varied. No 
consistent method of diagnostic methodology for minimal hepatic encephalopathy 
was adopted, other than mainly excluding patients with overt HE. However, in all 
studies, patients were considered to be in the early stages of liver disease and were 
considered to have minimal hepatic encephalopathy.
Some of the studies used patients who were due to receive transplantation and 
measures on neuropsychological tests were taken prior to transplantation. Again, this 
suggests an advanced stage of liver disease that might have impacted on test
21performances, thus making comparisons invalid. Further still, studies have tended to 
use different tests to assess cognitive and neuropsychological domains.
In summary, minimal hepatic encephalopathy is characterised by some 
patterns of cognitive impairment. Areas of functioning that have been adequately 
tested are psychomotor skills and tests of attention (although it can be argued that 
most neuropsychological tests measure attention). It may also affect memory, 
perception and constructive abilities.  Less is known about the pattern of memory 
impairment although spatial memory appears relatively preserved.
Studies have measured different areas of functioning although few have 
grouped different tests into main areas such as those measuring executive functioning 
or information processing domains. This demonstrates inconsistencies between 
studies surrounding areas of functioning to be assessed and how, i.e. by which tests. 
Therefore, differences between studies (with regards to tests used) have made some 
comparisons difficult. Further still, the extent of impairment is variable because a 
decrease in mental activity (attention) may impair several cognitive functions.
Patients with minimal hepatic encephalopathy may even exhibit ‘normal’ cognitive 
performances but overall productivity may suffer from inattentiveness and fatigue 
secondary to attention abnormalities (Das & Faber, 2003).
1.10.2  Type of Liver Disease and Cognitive Functioning
One criticism of research on cognitive functioning in liver disease is that 
studies where group classification is based on disease severity fail to differentiate 
between aetiologies of liver disease (Collie, 2005). However, some studies report 
cognitive impairment in patients with liver disease of specific aetiology and the main 
body of research has focused on patients with Hepatitis C Virus (HCV), Wilson’s 
disease (WD) and Alcoholic Liver Disease (ALD).
22As outlined by Collie (2005), there is as yet no consistent 'profile' of 
cognitive dysfunction in HCV. Again, methodological differences between studies 
have made generalisation of findings difficult, although one common finding is that 
greater disease severity is associated with greater cognitive dysfunction and patients 
display psychomotor impairment. Additionally, neuropsychiatric symptoms are a 
‘hallmark’ of WD, with clinical presentation in adulthood including personality 
changes and neurological signs (e.g. tremor and dystonia). WD patients display mild 
but clearly significant impairments in many cognitive functions compared with 
controls and most severely affected areas are on tests of attention and motor speed.
Further to this, there is a large body of literature demonstrating an association 
between chronic alcoholism and cognitive dysfunction (Collie, 2005). Cognitive 
impairments observed in chronic alcoholics without liver disease are commonly 
thought to include executive functions including abstraction, planning, problem 
solving and working memory, while patients with the neurodegenerative Wemicke- 
Korsakoff s disease typically display impairments in the formation and retrieval of 
new memory. Despite the large number of studies of alcoholism, there have been 
relatively few studies specifically investigating contributions of liver disease to the 
patterns of cognitive changes observed in alcoholics.
Several authors have hypothesised that cerebral and hepatic consequences of 
alcoholism may combine to produce more severe cognitive dysfunction in ALD 
patients than in non-ALD patients (Collie, 2005). However a consistent finding in the 
literature has been that ALD and non-ALD patients display equivalent levels of 
dysfunction on tests of learning and memory, simple and complex attention, 
psychomotor function and general intellectual ability. However, Tarter, Hegedus and 
Thiel (1987) found that ALD patients were impaired on tests of learning/memory and
23psychomotor functioning than other groups (with cirrhosis resulting from viral 
hepatitis).
Hilsabeck, Perry and Hassanein (2003) studied patients with chronic 
Hepatitis C and other types of chronic liver disease and used a brief 
neuropsychological testing battery. They found test scores of patients with chronic 
hepatitis C did not differ from those patients with other chronic liver diseases. 
However, there was a significant relationship between fibrosis stage and test 
performance, with greater fibrosis associated with poorer performance. However, 
both patients with and without cirrhosis exhibited cognitive dysfunction.
One consistent feature of the results from the above studies is that 
neuropsychological deficits have been observed in those with different types and 
stages of liver disease compared with matched controls. However, as yet few 
consistent studies have found marked differences between types of liver disease and 
lack of standard comparison groups in research can make comparisons of research 
findings difficult.
1.11  Treating Cognitive Deficits
A number of therapies have been shown to improve cognition in liver disease, 
including lactulose treatment, dietary protein manipulation and oral supplementation 
with branched chain amino acids. For example, minimal hepatic encephalopathy has 
been found to disappear in some cirrhotic patients after 8 weeks of lactose treatment, 
whereas other findings have found that MHE resolves in a lot fewer instances. In 
view of these mixed findings, there is currently no consensus regarding the most 
practical and effective treatment strategy for cognitive dysfunction in liver disease 
patients without overt hepatic encephalopathy.
241.12  Limitations of the MHE Hypothesis
Minimal hepatic encephalopathy remains a phenomenon that is poorly 
understood. While hepatic encephalopathy is a clearer, well-defined clinical entity, 
occurring relatively frequently in patients with liver disease, MHE is less well 
defined. There is no consistent, diagnostic criterion available (Collie, 2005). In 
clinical practice, liver consultants involved in each patient’s care usually determine 
judgement about the existence of hepatic encephalopathy. However, there has also 
been some debate around the existence of MHE and in spite of some evidence 
indicating that the diagnosis of MHE may be important, some clinicians believe this 
condition is irrelevant.  Research on MHE has often included liver disease patients 
without overt signs of hepatic encephalopathy but has not included a diagnostic 
measure of this syndrome.
However, it has been established that such patients with varying degree of 
liver disease severity, without overt signs of hepatic encephalopathy (e.g. personality 
disorders, inappropriate affective, behavioural and sleep disturbances and cognitive 
and psychomotor impairments), report cognitive alterations that can make it difficult 
to perform day to day tasks requiring correct cerebral function, such as driving, 
operating machinery and other work-related activities (discussed below). Therefore, 
a further understanding of the problems associated in those without overt features of 
hepatic encephalopathy is necessary in order to promote early identification and 
management of liver disease.
The cognitive profile associated with MHE is still under study. Although 
patients with liver disease can report cognitive alterations and difficulties performing 
daily tasks or work related activities, the exact range of deficits are unknown. 
However, research has suggested deficits in psychomotor speed and flexibility,
25verbal fluency, visual constructive abilities, frontal skills and attention. All of these 
have been tested adequately by the studies presented in Table 3 although the research 
has not assessed certain domains with a variety of neuropsychological tests and have 
instead used one or two to assess one particular skill. Memory ability in liver disease 
is less well understood and deficits have been observed in verbal but not spatial 
memory. Short-term and long-term memory with regard to both types of memory has 
not been adequately assessed. Additionally, few comprehensive batteries of 
neuropsychological tests have been conducted and in very few studies has data been 
compared to an appropriate number of healthy matched controls.
As MHE is understood to predispose individuals to HE, early detection of 
MHE can be beneficial in order to implement specific treatment strategies. Early 
recognition of impairment may allow the delay of disease. An early identification of 
patients at initial phases of hepatic encephalopathy may improve the quality of life 
and the prognosis of these patients (Das & Faber, 2003).
1.13  Causes of cognitive impairment in minimal hepatic encephalopathy: biological
In patients with mild cognitive dysfunction, the cognitive alterations are less 
clear. It is acknowledged that abnormalities in cognitive function exist in liver 
disease patients and individuals with both chronic liver disease and acute liver failure 
may demonstrate cognitive impairments compared to controls on neuropsychological 
tests.
Biological explanations have been used to account for these observations and 
it has been suggested that similar processes occur in both hepatic encephalopathy and 
minimal hepatic encephalopathy. There is a degree of confusion about the precise 
cause of such impairment and whether processes involved in both syndromes are 
identical. Research has suggested that possible causes of cognitive deficits in
26minimal hepatic encephalopathy are similar yet milder as those in hepatic 
encephalopathy (Collie, 2005). Some causes (i.e. the ammonia hypothesis, see 
below) are widely accepted although further research is required to make definite 
conclusions.
1.13.1 The ammonia hypothesis
The most popular biological explanation of MHE is the ammonia hypothesis. 
As outlined above, it has been suggested that ammonia levels are excessive in 
hepatic encephalopathy as a result of 1) malfunctioning astrocytes and lack of de­
toxification of ammonia and 2) and the non-conversion of ammonia to urea by the 
liver). It is thought that both these processes lead to a state of chronic 
hyperammonemia (Blei & Cordoba, 2001) and reduced cerebral blood flow in 
subcortical brain regions.
Therefore, increased ammonia could effect brain functioning and result in 
cognitive deficits in HE (Loudianos & Gitlin, 2000; Blei & Cordoba, 2001). In MHE, 
it is thought that similar yet milder processes occur which leads to an increased 
accumulation of ammonia. Further research is required to establish the link and the 
precise processes involved. Although this hypothesis is widely accepted, there are 
some limitations associated with it. For example, there remains some doubt as to 
whether excess ammonia consistently results in cognitive and functional disturbances 
in all patients with liver disease.
1.13.2 The role of the basal ganglia and subcortical structures
Collie (2005) outlines how the cognitive abnormalities are associated with 
increased toxic substances, such as those occurring in overt HE.  This is considered 
the case in WD, in which impaired copper metabolism leads to its accumulation in
27the basal ganglia although other CNS areas may be affected also (Medalia, Isaacs- 
Glaberman & Scheinberg, 1998).
Collie (2005) suggests that the pattern of cognitive deficits in both severe and 
less severe stages of liver disease (observed in both memory and psychomotor 
functions) reflect the involvement of both cortical and sub cortical areas. This is also 
the view of Blei and Cordoba (2001) who proposes that ammonia accumulates in this 
brain region in HE. However, it is also unclear as to whether processes are similar in 
both HE and MHE.
1.13.3  The systemic inflammatory response syndrome (SIRS)
While transplantation appears to alleviate cognitive dysfunction in studies of 
mixed aetiology, few studies have investigated long-term effects of this. Other 
researchers (Shawcross, Raines, Wright, Damik & Jalan, 2007) argue that there is no 
direct correlation between ammonia concentrations and severity of MHE, thus 
arguing against the role of ammonia per se and that other factors may be important. 
They outline (Shawcross et al, 2007) that the presence of a ‘systemic inflammatory 
response syndrome’ (SIRS) can result in poorer neurological outcomes detected by 
neuropsychological tests.
In general, liver transplantation results in improved cognitive function for 
most liver disease patients. While numerous studies have now reported that cognition 
improves from transplantation, others have demonstrated that very subtle 
impairments persist for at least 10 years post transplant (Collie, 2005).
1.14  Psychological explanations
There have been few investigations into the psychological implications of 
liver disease. Research has been carried out into health aspects (coping or quality of 
life issues) and psychological/clinical factors (mood issues) of living with a physical
28illness (Gleason, Yates & Philipsen, 2004; Martin, Sheridan and Younossi, 2002). 
However, to date little research has been carried out into living with various types of 
liver disease.
As outlined above, research has shown that those with different stages of liver 
disease have demonstrated a range of deficits in various domains of cognitive 
functions although the precise profile of such impairment is yet to be determined. 
Patients with mild forms of liver disease can complain of some mild cognitive 
impairment, such as reduced attention, concentration or memory. These complaints 
can be investigated further by neuropsychological testing which involves the 
administration of specific tests which measure specific aspects of functioning and 
often have implications for the functioning of particular brain regions (e.g. executive 
functioning and frontal lobes). The neuropsychological model/approach is often used 
to help establish particular ‘patterns’ of cognitive deficits observed in particular 
syndromes.
Collie (2005) outlined how the common symptoms of these diseases (e.g. poor 
quality of life, depression, and fatigue) cause a corresponding functional cognitive 
disturbance. For example, the most common symptom of Hepatitis C is fatigue (Goh, 
Coughlan, Quinn, 1999) and patients also report psychiatric symptoms including 
poor quality of life, depression and anxiety (Gleason, Yates & Philipsen, 2004;
Kraus, Schafer & Csef, 2000).  Chronic fatigue is also one of the most common and 
debilitating symptoms of cholestatic liver disease, affecting up to 68% of patients 
(Lindor, Dickenson, Baldus, 1994).
To date, studies of minimal hepatic encephalopathy have mainly investigated 
the impact on cognitive functioning. Although attentional deficits would explain poor 
test performances,  MHE may also affect multiple areas of functioning, including
29mood and general wellbeing. Although MHE has been associated with poor quality 
of life, few studies have explored this further and a clear understanding of relevant 
factors considered necessary for good quality of life is lacking. Additionally, in most 
of the studies investigating cognitive deficits in liver disease, few, if any, have taken 
psychological measures of mood such as anxiety or depression.
1.14.1  Quality of Life
Martin, Sheridan and Younossi (2002) proposed that a patient’s quality of life 
is an important measure in clinical research. They propose that less emphasis should 
be placed on a biomedical model of health to one that incorporates how people are 
affected in various social and psychological implications of disease.
A few studies have investigated quality of life in chronic liver disease and in 
those awaiting transplantation. Hicks, Larson and Ferrans (1992) reported quality of 
life in chronic liver disease patients was highest for aspects related to family life and 
then for health and functioning.  Additionally, Park, Park, Kim, Park, Hyan, Yun, Jo, 
Tak, Kweon, Kim, Choi and Park (2003) measured health related quality of life in 
patients with chronic viral hepatitis or cirrhosis. They found scores were significantly 
lower in the patient group than the control group and differences were more 
prominent in domains reflective of mental rather than physical health.
The effects of transplantation have been investigated by Belle, Porayko, Jay, 
Hoofhagle, Lake and Zetterman (1997) who found over 50% of recipients noted 
some level of distress after transplantation. The values on quality of life measures 
were considered comparable and somewhat lower than those found in a study of 
heart transplantation recipients. Patients did tend to be much happier at follow-up 
than at baseline, however, and their index of well-being was similar to that of the
30general population. At follow up, satisfaction was greatest with marriage and family 
life, followed by health.
1.14.2  Everyday functioning
Groeneweg, Quero, De-Bruijn, Hartmann, Essink-Bot, Hop & Schalm (1998) 
analysed the impact of minimal HE on daily functioning by administering the 
Sickness Impact Profile (SIP) -  a questionnaire consisting of 136 statements 
considering ambulation, mobility, body care, social interactions, alertness, emotional 
behaviour, communication, sleep and rest, home management, recreation and 
pastime or work, to 179 cirrhotic outpatients. Forty-eight patients suffered from 
minimal hepatic encephalopathy, while the remaining 131 patients were normal with 
regard to the clinical examination, psychometric test results and EEG. The authors 
found a diminished level of daily functioning in the patients with minimal HE 
reflected by significantly more impairments in all categories of the SIP.
The implications of MHE on occupational functioning are illustrated by 
Hamster (1982). Hamster studied blue-collar and white-collar workers with MHE 
and their earning capacity was compared.  73% of the cirrhotics who were blue- 
collar workers had an impaired earning capacity, whereas 50% of white-collar 
workers were fit for work in the presence of MHE. This was due to the preservation 
of verbal abilities that were less affected by MHE. This illustrates the importance of 
considerable impairment of motor performance in MHE where verbal skills remain 
intact.
O’Carroll, Hayes, Ebmeirer, Dougall, Murray, Best, Bouchier and Goodwin 
(1991) suggested subtle impairments of cognitive function may be an important 
cause of occupational and psychosocial morbidity in patients with chronic liver 
disease although further research is required to understand possible mechanisms.
31Schomerus, Hamster, Blunck, Reinhard, Mayer & Dolle (1981) argued MHE 
had a major impact on patients’ daily living and ability to perform everyday tasks. In 
their study, 40 cirrhotic patients without clinical signs of HE and a control group of 
12 patients with alcoholic pancreatitis underwent a comprehensive psychometric 
examination used for expert evaluation of the capacity to drive a vehicle. Of the 
cirrhotic patients, 60% were considered unfit to drive, in 25% driving capacity was 
questionable and only 15% - all of them non-alcoholic cirrhotics -  were considered 
fit to drive.  In contrast, 75% of the patients with alcoholic pancreatitis were 
considered fit to drive.
However, the effect of  MHE on the risk of automobile accidents is still not 
settled. Two studies that have evaluated driving on a real test ‘on the road’ have 
reached different conclusions. These discrepancies may be explained by differences 
in the characteristics of the patients and the driving tests. It is thought MHE does not 
affect all patients to the same extent. The impairment of attention and speed of 
mental processing, characteristic of MHE, affects the ability to react to hazardous 
situations. However, driving is a complex activity that depends on many factors, 
especially premorbid skills.
However, a decline in cognitive function is believed to increase the risk 
attention, memory and motor co-ordination, loss of concentration, drowsiness, 
altered sleep patterns and confusion. As yet, there are no clear guidelines as to 
whether patients diagnosed with MHE should carry on driving.  The Driving 
Standards Authority (DSA) requires anyone taking a driving test in the United 
Kingdom to pass a theory test in additional to the practical component. From 14 
November 2002, the theory test has also included a test of hazard perception skills. 
Due to findings suggesting patients with liver disease are more likely to be
32considered unfit to drive (Schomerus, Hamster, Blunck, Reinhard, Mayer & Dolle 
(1981), there has been some speculation over whether those with liver disease are 
able to adequately identify hazards due to possible cognitive deficits
In summary, studies have shown how quality of life and work related 
activities are affected in liver disease and this has been attributed to cognitive 
deficits.  It can be suggested that this has serious implications for effects of liver 
disease on mental health.  Collis & Lloyd (1992) however outlined how this topic has 
been relatively neglected in the psychiatric literature.
1.14.3  Anxiety and depression
There have been some studies investigating the psychological implications 
(e.g. anxiety, depression) of living with an illness. For example, it is widely 
documented that depressive disorders are more common in patients with physical 
illness than in those without, with up to one-third of medical in-patients reporting 
mild to moderate symptoms of depression (Rodin & Voshart, 1986).
Singh, Goyowski, Wagner & Marino (1997) looked into depression in those 
with end stage Hepatitis C and other types of liver disorders. They found that patients 
with Hepatitis C were more likely to report being significantly more depressed than 
those patients with other forms of liver disease, although the reasons were 
inconclusive. However, they also found this patient group reported significantly 
more pain and proposed this was possibly a reason.
Forton, Thomas, Muiphy, Allsop, Foster, Main, Wesnes & Taylor-Robinson 
(2003) proposed that patients with chronic hepatitis C (HCV) infection frequently 
report depression, fatigue and a perceived inability to function effectively.  Several 
other studies have also suggested that patients exhibit low quality of life scores that 
are independent of disease severity (Forton et al, 2001).
33MacHale (2002) postulated that there are particular issues around 
antidepressants in hepatic disease in that the sedative and constipating side-effects of 
antidepressants may precipitate or unmask sub clinical hepatic encephalopathy.  This 
would have psychological implications, in that terminating antidepressants due to 
such effects might result in increased low mood.
Anxiety is a common experience in chronic illness and in those with end- 
stage liver disease, it is also associated with the stress of waiting for a donor organ to 
become available. Quality of life, work, family and social roles are all impaired and 
these losses may also contribute to depression. Again, most of the available research 
on anxiety in liver disease has tended to look at this in end-stage liver disease.
Chappell and Case (1997) looked at levels of anxiety experienced by adult 
liver transplant patients immediately before surgery and at potentially stressful times 
throughout the recovery process, and levels were high at all stages. However, it can 
be suggested that anxiety levels are also high in patients with less severe stages of 
liver disease, especially during the periods after having been given a diagnosis as this 
is a period where increased worry and concern about health is experienced.
The available research into liver disease has tended not to focus on the 
prevalence of anxiety and depression in those with less severe types of liver disease. 
The research has also not investigated consistently anxiety or depression  levels 
found in patients with various stages or severities of liver disease, as determined by 
Child Pugh score, for example.  Therefore, the prevalence of low mood/depression 
and anxiety remains unknown in patients with varying stages of liver disease.
To date, minimal hepatic encephalopathy is understood to be associated with 
poorer quality of life and increased work disability. However, as Ortiz (2005) 
outlines, a major challenge is separating the effects of MHE from those of the disease
34causing MHE. Research has suggested MHE may have an independent effect on 
quality of life and can be considered mild enough that effects on basic life activities 
(i.e. shopping, using public transport, dressing, etc) are not anticipated. However, the 
observed impairments of attention, executive function and psychomotor skills may 
impair complex activities such as planning a trip, handling finances, gardening, 
performing a job or driving a car.
The influence of MHE will depend on the demands of the job, the severity of 
neuropsychological impairment and the possibilities to compensate for deficits. For 
instance, the impairment of fine motor skills that characterises MHE is critical for 
those who handle machinery.
1.15  Further areas for research
The precise spectrum of deficits in minimal hepatic encephalopathy remains 
unknown. With regard to cognition, the full extent of impairment is uncertain in 
those without overt signs of hepatic encephalopathy, although significant proportions 
of patients present with psychomotor complaints.  Few comprehensive batteries of 
neuropsychological tests have been conducted and in very few studies has data been 
compared to an appropriate number of healthy matched controls, or have taken 
premorbid IQ levels. The cause of such observed deficits is also unknown.
As outlined above, effects of MHE have mainly been concerned with 
cognition, yet MHE may affect mood and feelings, particularly when considering 
research that has suggested poor quality of life.  The effects of mood (e.g. anxiety or 
depression) have not been adequately taken into account and how they might impact 
on a patient’s cognitive functioning. Therefore, the prevalence of anxiety and 
depression in liver disease is important to consider from a clinical perspective. 
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44Part 2: Empirical Paper
The Impact of Liver Disease on Cognitive 
Functioning and Mood
45Abstract
It has been suggested that subgroups of patients with liver disease have mild 
cognitive alterations and demonstrate poorer performances on neuropsychological 
tests, compared with matched controls. Impairments on attention and psychomotor 
speed have been consistently demonstrated (Mechtcheriakov, Graziadei, Mattedi, 
Bodner, Kugener, Hinterhuber, Marksteiner & Vogel, 2004; Pantiga, Rodrigo, 
Cuesta, Lopez & Arias, 2003). This has been termed minimal hepatic 
encephalopathy (MHE) -  a syndrome that occurs in patients without overt symptoms 
of hepatic encephalopathy. The full spectrum of cognitive impairment in MHE is 
unknown, as is their cause, and biological and psychological explanations have been 
proposed (Collie, 2005).
The aim of the current research is to investigate the nature of cognitive 
deficits experienced in patients with liver disease by investigating performances on 
neuropsychological tests. Tests of speed/motor functioning, frontal/executive 
functioning, verbal and spatial memories are included in the study. Performances on 
all tests are compared with 1) controls and 2) between groups of patients with 
different stages of liver disease.  Measures of depression and anxiety are also taken.
The findings show patients with liver disease have worse performances on 
neuropsychological tests than controls, especially with regards to executive 
functioning and motor speed. Deficits are not attributed to anxiety or depression. 
Additionally, severity of liver disease is associated with worse performances on 
neuropsychological tests generally, particularly tests of motor functioning and 
executive function. However, patients with less severe liver disease demonstrate 
poorer performances on tests of verbal memory than patients with more severe stages 
of liver disease do. Overall, the results suggest that severity of liver disease leads to
46greater cognitive deficits in some domains. Implications for future research and 
clinical practice are discussed.
471.1 Introduction
The British Liver Trust (2007) has warned that the prevalence of liver disease 
in the United Kingdom is likely to increase dramatically in the future as unhealthy 
lifestyles take their toll. This has serious medical, occupational and psychological 
implications. Minimal hepatic encephalopathy (MHE) has been defined as a 
syndrome that is characterised by an absence of clinical signs of encephalopathy (i .e. 
impaired functioning, changes in reflexes, asterixis, tremors and fluctuations of 
vigilance), yet a presence of cognitive disturbances. These can be detected upon 
neuropsychological testing (McCrea, Cordoba, Vessey, Blei & Randolph, 1996). 
Deficits can also effect quality of life (Groeneweg, Quero, De-Bruijn, Hartmann, 
Essink-Bot & Schalm, 1998) and work-related activities (Hamster, 1982).
Deficits have been consistently found on tests of psychomotor abilities, 
attention and visuo-constructive ability (Mattarozzi, Stracciari, Vignatelli,
D’Alessandro, Morelli & Guarino, 2004).  However, the full extent of cognitive 
impairments in minimal hepatic encephalopathy,  and their possible cause, remains 
unknown.
Cognitive changes are evident in all types and severity of liver disease and 
there is little doubt that they are associated with serious functional consequences for 
patients, including mood, overall quality of life, decreased ability to perform normal 
day-to-day tasks such as driving and operating machinery, as well as disruptions to 
the sleep-wake cycle (Collie, 2005; Schmoerus & Hamster, 1998).
1.2 Liver Disease
Liver disease is a term given to many diseases and disorders that cause the 
liver to function improperly (Stone, 2004). It is an acute or chronic damage, usually 
caused by infection, injury, exposure to drugs or toxic compounds, an autoimmune
48process or by genetic defect. The disease can also be categorised as the effect it has 
on the liver. Hepatitis is an inflammation of the liver, cirrhosis involves scarring and 
progressive cell death, stones can form blockages, and fatty liver and cancer are rare 
but can be life threatening.
Although there are many different causes of liver disease, it is often due to 
excess alcohol consumption. Alcohol consumption will increase the rate of 
progression of cirrhosis from whatever cause. The Department of Health (2001) 
stated that the rising trends in death from cirrhosis seen in England are unusual 
compared with our European Union neighbours, and it has been recognised that 
heavy episodic drinking is a noticeable feature of people’s social lives in the United 
Kingdom. This has caused the Department of Health to highlight alcohol 
consumption as a key in its National Alcohol Strategy in Spring 2000.
1.2.1  Prognosis
The Child Pugh (CP) or Child Turcotte Pugh Score determines prognosis of 
chronic liver disease, mainly cirrhosis.  It can also be used to understand severity of 
liver disease, Child Pugh stage A is considered to be associated with better liver 
functioning than Child Pugh stages B and C (Groeneweg, Mooreland, Quero, Hop, 
Krabbe & Schalm 2000).
1.2.2  Hepatic Encephalopathy
With severe liver impairment, toxic substances normally removed by the liver 
accumulate in the blood and impair brain cell functioning. These toxic substances 
can travel directly to the brain without being modified and lead to damage to the 
brain and nervous system. Signs can include impaired cognition, behavioural 
changes, a flapping tremor (asterixis) and a decreased level of consciousness, 
including coma and ultimately death. These occur in hepatic encephalopathy (HE).
49The instance of HE in cirrhosis patients is high -  Wolf (2007) proposed signs 
of HE occur in approximately 70% of cases. HE seriously impairs daily functioning 
in both physical and psychological domains and the prognosis of HE is poor, with 
survival 1-year postdiagnosis of approximately 40% (Bustamante, Rimola &
Ventura, 1999).
Hepatic encephalopathy is thus understood as a “clinical picture that can 
present when damage to the brain and nervous system has occurred as a complication 
of liver disorders” (Pantiga, Rodrigo, Cuesta, Lopez & Arias, 2001). It has not been 
attributed to any one cause or mechanism/toxic substance but is believed to stem 
from the combined effect of several factors (Pantiga et al, 2001). A role for advanced 
ammonia levels in HE has also been identified.
1.2  .3  Grading of Hepatic Encephalopathy
The clinical symptoms of hepatic encephalopathy are graded into 4 classes, 
with predominant respect to the disturbance of consciousness.  Usually, different 
stages of severity are considered to correspond with different grades of hepatic 
encephalopathy. As outlined by Weissenbom (1999), HE grade 1  is characterised by 
sleep disturbances, psychomotor slowing, attention and concentration deficits. 
Patients with grade 2 HE present with lethargy and disorientation.  Additionally, 
several neuromuscular symptoms like flapping tremor, ataxia and slurred speech may 
be observed.
In grade 3 HE the patients are drowsy, as well as showing a characteristic 
disturbance of speech with preservation and echolia. Grade 4 is associated with 
hepatic coma. Although prognosis of HE is poor, early detection can lead to more 
effective management and medical treatments.
501.2.4  Minimal Hepatic Encephalopathy
Minimal hepatic encephalopathy (MHE) has been considered a mild stage of 
hepatic encephalopathy. Patients with liver cirrhosis but no clinical signs of hepatic 
encephalopathy  (and sometimes termed grade 0 HE -  Weissenbom, 1999) have been 
observed to have worse performances on neuropsychological tests than controls 
despite a fairly ‘normal’ clinical presentation. However, it has also been observed 
that cerebral function is altered in such patients (Collis & Lloyd, 1992).
Patients with MHE can present with some cognitive complaints, making it 
impossible for them to perform normal day-to-day activities, such as driving and 
work-related activities (Schomerus, Hamster, Blunck, Reinhard, Myer & Dolle,
1981).  It is also believed that MHE signifies increased morbidity and poor qualities 
of life in both the physical and psychological domains (Groeneweg, Quero, De 
Brujin, Hartmann, Essink-Bot & Schalm, 1998).
1.2.5  Prevalence and Diagnostic Criteria
It believed that minimal hepatic encephalopathy probably predisposes 
individuals to hepatic encephalopathy but the prevalence of MHE is understood to 
vary. It is generally accepted that among patients with a Child Pugh score of A 
(better liver function), less patients are likely to have MHE. However, in patients 
with a Child Pugh score of B or C, (indicating more advanced cirrhosis), MHE is 
probably likely in approximately 50 % of them (Collie, 2005).
There is no uniform test for the diagnosis of MHE and it usually relies on the 
clinical judgement of the consultant and medical professionals involved in the care of 
each patient. Usually, this depends on a presence of engagement, normal speech and 
information processing abilities (attention and concentration) and an absence of overt
51symptoms associated with hepatic encephalopathy (as outlined earlier in Table 2) at 
the time of clinical presentation.
The Psychometric Hepatic Encephalopathy Score (PHES) test has been 
developed for diagnostic purposes but this battery has been criticised for being rather 
limited. For example, various components of attention and information processing 
considered necessary for driving/reducing risk of accidents are not directly measured. 
Therefore, inconsistencies in the diagnostic criteria and methods have contributed to 
wide variations in reported prevalence of MHE. It has been reported to occur in 
anywhere from 30% to 84% of patients with liver disease, depending on criteria used 
to identify it.
Nevertheless, it is now acknowledged that abnormalities in cognitive function 
are a common complication of liver disease and that those with both acute and 
chronic liver disease may demonstrate cognitive impairments on neuropsychological 
tests when compared with healthy, matched controls, including impairments in 
memory, attention and psychomotor function. Such impairment is considered mild in 
MHE, yet it may represent a significant complication of liver disease that may 
negatively impact on quality of life and normal daily activities. It is felt early 
identification of cognitive manifestations of liver disease is important for timing and 
monitoring of treatment.
1.2.6  Summary of Research Findings on Cognitive Deficits
The most consistent finding has shown deficits in attention and motor skills. 
For example, Mattarozzi et al (2005) found that patients with MHE exhibited 
reduced cognitive performance compared with controls on several attention 
components including selective and visuospatial attention (visuospatial attention was 
assessed by the Trail Making Test (TMT) A and B and selective attention was
52assessed by the Stroop colour test). Similar findings have been obtained in other 
studies (i.e. Mechtcheriakov, Graziadei, Mattedi, Bodner, Kugener, Hinterhuber and 
Vogel, 2004; Pantiga, Rodrigo, Cuesta, Lopez & Arias, 2003). The impact of early 
stage cirrhosis on other cognitive domains, (i.e. memory and verbal fluency), are less 
well understood.
Therefore, the exact range of cognitive deficits in MHE is unknown. Few 
studies have used large batteries of neuropsychological tests, controls or measures of 
premorbid IQ. Other studies have also demonstrated discrepancies between self- 
reported deficits by patients and actual observed deficits on neuropsychometric tests. 
For example, several cognitive complaints (decreased attention, confusion and 
memory difficulties) are related to MHE but a significant number of patients do not 
always exhibit abnormalities on tests that measured such domains.
1.2  .7  Possible Causes of Cognitive Deficits
Cognitive deficits in early stages of liver disease have been well documented 
and a number of explanations have attempted to offer an explanation of the 
underlying causes. Magnetic resonance-spectroscopy and positron emission 
tomography studies have shown metabolic alterations in different brain areas, such as 
occipital and cingulate regions which are supposed to be involved in the control of 
attention and in visual-motor co-ordination (Lockwood, Weisenbom, Bokemeyer & 
Burchert, 2002). A role for frontal lobes and sub cortical structures, involved in 
executive functioning and motor tasks, has also been identified.
Due to the scaning within the liver, cirrhosis leads to obstruction of the 
passage of blood through the liver causing portal hypertension. This is when it is 
difficult for blood from the intestines to go through the liver to get back to the heart. 
Furthermore, in liver disease, the damaged liver may not be functioning as well as it
53should be so the blood that does travel through the liver may not be adequately 
detoxified.
The toxic substances that accumulate in liver disease and affect the brain are 
not well understood. It has been proposed that the cognitive alterations observed in 
more advanced cirrhotic patients can be attributed to increased ammonia levels. In 
overt HE, cognitive and behavioural changes are thought to result from alterations in 
neurotransmission caused by the entry of ammonia.
In MHE therefore, it is possible that cognitive abnormalities result from 
milder but similar pathogenic processes such as those occurring in overt HE. That is, 
these diseases may indirectly affect brain function, resulting in cognitive impairment. 
Ammonia is normally converted to urea by the liver and can cross the blood-brain 
barrier where it causes support cells of the brain (astrocytes) to swell.
Exact effects of ammonia on psychological functioning are poorly understood 
although levels of ammonia are frequently found in the environment, i .e. in various 
household products such as cleaners. It is also found in water, soil and air, and is a 
source of much-needed nitrogen for plants, animals and humans. Most of the 
ammonia in the environment comes from the natural breakdown of manure, dead 
plants and animals.
Other explanations of the cognitive deficits in MHE suggest that the presence 
of a systemic inflammatory response syndrome (SIRS) confers to poorer 
neurological outcome (Rose & Jalan, 2004) and that inflammation may be important 
in modulating the cerebral effect of ammonia in liver disease. Additional 
explanations have involved the neuro-inhibitory neurotransmitter GAB A, which is 
found in excessive amounts in samples of those with hepatic encephalopathy. 
Therefore, this could play a role in the pathogenesis in minimal hepatic
54encephalopathy. Other precipitating factors include electrolyte imbalance, drug use 
and miscellaneous factors such as infection and surgery.
An alternative hypothesis is that the additional symptoms of these diseases 
(e.g. fatigue, depression, impaired quality of life) cause a corresponding functional 
cognitive disturbance. Fatigue has been associated with hepatitis C (Goh, Coughlan 
& Quinn, 1999) and cholestatic liver disease (Lindor, Dickenson, Baldus, 1994). 
Hepatitis C patients also report psychiatric symptoms including depression and 
anxiety and poor quality of life (Forton, Thomas, Taylor-Robinson, Murphy, Allsop, 
Foster, Main J, Wesnes & Taylor-Robinson 2003).  Further studies have found 
significant psychological distress in patients with chronic, non-alcoholic liver disease 
(Davis, De Nour, Shouval & Melmed, 1998).
As outlined earlier, Park et al (2003) found that patients with chronic hepatitis 
C had significantly lower scores on measures of health related quality of life than 
controls. The  difference was more prominent in domains reflective of mental as 
opposed to physical health. Park et al also compared performances across different 
severity of liver disease (as determined by Child Pugh stage) and scores on domains 
of mental health were lower in less severe stages of liver disease (i.e. indicating 
poorer quality of life scores).  This study therefore constitutes an attempt to 
understand general wellbeing across different stages of liver disease.
Further studies are required to determine the extent to which different above 
explanations interact and to date findings are mixed. Cordoba, Flavia, Jacas, Sauleda, 
Esteban, Vargas, Esteban & Guardia (2003) argued hepatitis C causes poor quality of 
life even in the absence of major cognitive impairment and Forton, Thomas, Murphy, 
Allsop, Foster and Main (2003) argued cognitive impairment can be unaccounted for 
by depression. As outlined above however, few of the studies investigating cognitive
55deficits in liver disease have taken psychological measures of mood, such as anxiety 
or depression.
1.2.8  Further research possibilities
The research on liver disease and cognitive functioning to date has 
investigated cognitive functioning in those without overt features of encephalopathy. 
Few studies have used comprehensive test batteries and the precise patterns of 
deficits are unknown. This is important to determine however as early detection of 
impairments with lead to earlier management and treatment. Therefore, this is 
required in further research.
Additionally, research on minimal hepatic encephalopathy has mainly been 
concerned with cognition, yet MHE may exert effects in other areas. The impact of 
mood (e.g. anxiety or depression) on cognitive functioning in liver disease has not 
been investigated. Furthermore, an understanding of possible mood states in liver 
disease, as well as the kinds of deficits experienced in varying severity of liver 
disease (as determined by Child Pugh score) will lead to a further understanding 
about how liver disease exerts its effects.
The current research is a preliminary investigation into the spectrum of 
possible difficulties people with early stage cirrhosis experience. It is anticipated 
that patients will show more performance deficits on neuropsychometric tests 
compared with matched controls. This has been observed in previous research 
although the full spectrum of deficits is unknown.
Biological explanations of minimum hepatic encephalopathy include 
increased ammonia levels, (as in hepatic encephalopathy), and there is agreement 
that both syndromes are associated with similar processes. This had led to the 
‘ammonia hypothesis’ -  in MHE, it is thought that processes are less extreme and
56ammonia levels are milder than in HE. Additionally, Pantiga, Rodrigo, Cuesta, 
Lopez and Arias (2001) argue the patterns of cognitive deficit in liver disease 
increase according to severity of liver disease, and that performances on 
neuropsychological tests will be worse in more severe cases. This suggests that as 
the severity of liver disease increases, the higher the accumulations of ammonia in 
the blood/brain support cells which can contribute to cognitive impairment in liver 
disease.
Therefore, it is anticipated that in the current study, the patients with Child 
Pugh scores of C (indicating more severe liver disease) will be more impaired on 
performances on neuropsychological tests compared to patients with Child Pugh 
scores of A (indicating less severe stage of liver disease). The proposed research 
will investigate the effects of early stage cirrhosis on a number of domains of 
cognitive functioning, to be assessed by standardised measures. Additionally, a 
measure of psychological functioning (anxiety and depression) will be included. 
Finally, a measure of premorbid IQ will be taken.
1.2.9  Study aims and hypothesis 
The aim is to:
1)  Identify the range, nature and extent of neuropsychological 
deficits through standardised/self-report measures in patients with different 
levels of severity of liver disease, as measured by Child Pugh scores and 
compared to controls;
2)  Explore the association between cirrhosis and mood.
1.3  Method
571.3.1  Design
The present study is a cross sectional, between subjects study comparing 
neuropsychological performance in 27 patients with liver disease with 22 healthy 
volunteers (controls). The controls were matched to the cirrhotic group for years 
spent in education and estimated premoibid ability/intelligence.
1.3.2  Ethical Approval and Informed Consent
The joint UCL/UCLH committee on the Ethics of Human Research, 
Committee A, granted ethical approval for this research project (Appendix A) and 
written informed consent was obtained from participants (Appendix B).
Approval involved making an amendment to a previous study concerned with 
investigating hazard perception in a cirrhotic patient group. The amendment was 
made in order to perform the neuropsychological tests on cirrhotic patients. The 
hazard perception part of the study is yet to be completed. Patients were 
compensated for their time.
1.3.3  Participants -  Patients with Liver Disease
A sample of 27 participants were studied (11 women and 16 men), mean age 
54.81 years (SD = 9.05). Patients were recruited from the liver clinic at University 
College London Hospital. The Registrar was given the patient inclusion/exclusion 
criteria and forwarded on contact details of suitable patients to the researcher. All 
patients were receiving ongoing monitoring by the liver consultant and were 
diagnosed with hepatic cirrhosis, following physical and biological examinations by 
the consultant involved in their care at the liver clinic.
The Child Pugh score of each patient was calculated and given to the 
researcher at the time they were referred for the study. Once referred, patients were
58contacted by telephone and the study was explained before asking whether they 
would like to participate in the study.
Patients were subdivided into groups according to their Child Pugh score. 
Accordingly, 9, 8 and 10 patients were in each of the Child A, B and C groups 
respectively. Cirrhosis was diagnosed by using classical clinical and analytical 
criteria and was confirmed by liver biopsy.
1.3.4  Exclusion criteria
Patients were excluded from the study if they had hepatic encephalopathy. 
The liver consultant assessed this by the absence of symptoms usually observed in 
HE (please see Table 2 , Part 1) before the patient was referred for the study. This 
was based on clinical assessment and patient self-reports of typical symptoms of HE 
as outlined earlier. They were also excluded if they were older than 65 years of age 
or had been diagnosed with any psychiatric or neurological problems. This was the 
responsibility of the medical registrar who checked patient files and medical 
notes/histoiy before referring patients to participate in the study. On this basis, the 
registrar also excluded patients if they had ongoing addictions to psychotropic drugs 
or alcohol, cardiovascular disease, renal dysfunction, recent gastrointestinal bleeding, 
malignancy or pregnancy. Based on these criteria, two patients were excluded from 
the study.
1.3.5  Matched controls
The control group (CG) comprised 22 healthy volunteers, mean age 45.59, 
(SD = 10.92). This group participated in a similar study and served as a control 
group in a study that investigated effects of organic phosphate poisoning in farmers 
in 2006 in Norfolk. All control participants responded to an advertisement seeking 
participants for the study at that time. Data was used to serve as a comparison group
59and all participants in this control group were screened for physical, neurological or 
psychiatric problems (determined by clinical interview before the participant was 
included in the study).  The educational level and premorbid IQ level in the CG were 
similar to those in the cirrhotic groups.
1.3.6  Neuropsychological Assessment
All participants underwent detailed psychometric testing. Only well known, 
reliable and clinically sensitive measures were selected for inclusion in this test 
battery. As was mentioned in the introduction, previous studies have often used 
limited test batteries that 1) do not assess classes of cognitive function and 2) have 
not included any measures of mood.
Tests were selected which would assess a broad range of cognitive functions 
consisting of premorbid IQ, language skills, memory functioning (verbal and visual), 
information processing speed, executive function and visuo-perceptual ability. Tests 
were also chosen on the basis of minimal administration time. Following this, tests 
were clustered as follows:
1.3.7  PremoibidlQ:
The National Adult Reading Test (Nelson, 1982) was used to assess 
premoibid ability. This estimate of IQ is relatively resistant to organic brain damage 
and correlates highly with Wechsler Adult Intelligence Scale-Revised (WAIS-R) IQ 
scores in healthy adults (Crawford, 1989).
1.3.8  Subtests from the WAIS-R
Subtests from the WAIS-R were included, two that measure verbal IQ 
(Vocabulary and Digit Span) and two that measure non-verbal IQ (Block Design and 
Digit Symbol).
601.3.9  Memory:
The Adult Memory and Information Processing Test Battery (AMIPB: 
Coughlan and Hollows, 1985) was used to assess visual and verbal memory. There 
are four main subtests that assess memory functioning: a list learning task, prose 
recall (immediate and delayed), a design learning task and immediate and delayed 
recall of a complex figure.
For the list learning tasks, scores for overall numbers of words recalled 
during the tasks, as well as after a distraction, were used. Performance on the design- 
learning task was also assessed this way (i.e. scores for performance throughout the 
task and score for memory of the task after a distraction task).  In both tests, 
distractions involved the administration of another similar task before memory for 
the original material was tested. For list- learning, another list was administered 
before test recall and in design-learning, another design was administered before 
recall of the original design was tested.
For the complex figure task, scores for both the immediate and delayed recall 
of the figure were used. Prose recall involved the recall of a short story (immediate 
and delayed, e.g. after approximately half an hour of further test administration).
1.3.10 Mental Flexibility (executive/frontal lobe function)
The Stroop test (Ternary et al, 1988) was included as a measure of mental 
flexibility and frontal lobe function. Performance on the verbal fluency task (FAS: 
Godowsky et al, 1967) was used to assess expressive language and frontal lobe 
function. For the first part, participants are required to list as many words beginning 
with the letters F, A and S and for the semantic part, participants are to list as many 
animals and household objects as they can.  All tasks are to be completed in one 
minute. Trails B (Spree & Strauss, 1991) was also included to assess
61frontal/executive function and this involves joining numbers and letters from lowest 
to highest and in alphabetical order.
1.3.11  Information Processing Speed Tests
AMIPB Information Processing Speed Tests (Coughlan & Hollows, 1985) 
were used in the test battery. Separate measures of mental and motor speed can be 
calculated from this test. Two scores for were used and these assessed how long it 
took participants to complete the task (‘Task A’ = total amount of correct responses 
within a time limit; ‘Speed’ = total number of digits crossed within a time limit).
Trail Making A (Spree & Strauss, 1991) was also included in the battery which 
involved looking at scores to 1) join numbers form lowest to highest. This involved 
calculating the time taken in total to complete the task and the time (in seconds) is 
the overall score.
1.3.12  Psychological Measures
The Hospital Anxiety Depression Scale (HADS: Zigmond & Snaith, 1983) 
was administered to assess participants’ level of anxiety and depression at the time of 
testing. This measure is designed to detect the presence and severity of anxiety and 
depression. It is a self-report measure and seven questions relating to anxiety are 
indicated by an ‘A’ while seven questions relating to depression are shown by a ‘D’. 
Respondents are asked questions relating to their experiences of anxiety and 
depression over the last week. Each question has four responses (measured on a four 
point likert scale ranging from 0 (not at all) to 3 (nearly all of the time). Total scores 
are calculated for each of the subscales of anxiety and depression.  Scores of 0-7 on 
each respective subscale are considered normal, with 8-10 borderline and 11 or over 
indicating clinical ‘caseness’.
62As outlined by Roberts, Bonnici, Mackinnon & Worcester (2001), reliability 
of the HADS is .98 for total score, .85 for anxiety subscale, and .80 for depression 
subscale. Test-retest reliability has produced coefficients over a two month period for 
the total score, anxiety subscale, and depression subscale (.79, .79, and .63 
respectively). With regard to validity, Correlation coefficients between the HADS 
and Symptom Checklist 90 scale were .73 (anxiety subscale) and .67 (depression 
subscale (Bjelland I, Dahl AA, Haug TT, Neckelmann, 2002)
The Hospital Anxiety and Depression Scale is a well-known, reliable and 
valid instrument and is often used to assess the role of emotional factors in clinical 
practice. A brief questionnaire is provided, which takes between 5-10 minutes 
approximately to complete. Many studies have confirmed the validity of the Hospital 
Anxiety and Depression Scale in the setting for which it was designed. Other studies 
have shown it to be a useful instrument in other areas of clinical practice. Patients 
have no difficulty in understanding the reason for request to answer the 
questionnaire.
1.3.13  Procedure
Data from the neuropsychological examination were collected from patients 
attending the outpatient clinic of Hepatology, University College London Hospital 
between November 2006 and June 2007. All participants provided their signed 
consent and were given an information sheet explaining the puipose of the study 
(Appendix B).
The Neuropsychological tests were administered first. This batteiy was 
followed by the completion of psychological measures and brief clinical interview, 
asking about current occupational status, past occupational history, level of education
63and gave the opportunity for each patient to elaborate on any aspect of current 
difficulties experienced.
1.3.14  Statistical Power
Finding comparable studies in order to calculate power calculations proved 
difficult. As was mentioned in the introduction, studies have utilised different 
methodologies, populations, psychological tests and control groups making direct 
comparisons problematic. However, studies by Pantiga et al (2001) found large effect 
sizes between cognitive function and cirrhotic/control participants on tasks of motor 
speed and mental flexibility, indicating that future studies would require a small 
sample size (6-8 patients with liver disease and 6-8 controls).
1.3.15  Data analysis and Statistical procedures
The data was corrected for age when required. On subtests of the WAIS-R, 
mean raw scores were converted to age adjusted scores by the use of the 
corresponding manual. On other tests within each domain studied, age was included 
as a covariate in statistical tests that analysed the data. The neuropsychological tests 
were grouped according to domain of psychological functioning.
641.4  Results
Table 4 gives the group characteristics of the study, in terms of age, Premorbid 
IQ and measures of anxiety and depression on the Hospital Anxiety and Depression 
Scale.
Table 4: Group Characteristics Between Patients and Controls
Group Age Premorbid IQ HADS A HADS D
Patients 54.81 109.74 6.81 5.33
N = 27 (9.05) (6.24) (4.31) (3.43)
Controls
N = 22 45.59 111.27 4.45 1.95
(10.92) (6.72) (2.80) (1.61)
t(23)= 3.23* t(23)=.82 t(23)=2.21** t(23)=4.25**
*P<0.05;**P<0.01
Separate Independent t -  tests were performed to test the difference between the 
two groups (patients vs. controls) on the variables of age, premorbid IQ, and measures of 
anxiety and depression as determined by the Hospital Anxiety and Depression Scale 
(HADS A and HADS D).  These showed a significant difference between the groups in 
terms of Age, (t (25) = 3.23, P<0.05); HADS A (t (25) = 2.21, P<0.01) and HADS D (t 
(25) = 4.25, P<0.01). Patients were significantly older and showed greater depression 
and anxiety,  however, the means did not indicate clinically relevant levels of anxiety 
or depression. There were no significant differences between groups in terms of NART 
Premorbid IQ, (t (25)  = .82, P>0.05)
1.4.1  Distribution of Variables
65The distribution of the data was examined. The skew and kurtosis of two 
variables (the scores on Task A and Stroop) were over 2, so square root transformations 
were applied to both variables
1.4.2  Stage 1  -  Liver disease patients and controls
Stage 1  of the data analysis involved investigating performances on 
neuropsychological test between patients and controls so as to test out the hypothesis 
that patients with liver disease will have poorer performances than the controls on 
neuropsychological tests.
The tests were clustered into related sub-groups for the purposes of conducting 
multiple analyses of variance so as to control for multiple testing without overly 
conservative thresholds of significance. These were WAIS-R subtests, test of motor 
speed, verbal and spatial memory and frontal/executive functioning.  Anxiety and 
depression scores were entered as covariates in all analyses to control for the effects of 
these variables. Age was also entered for all but the WAIS-R subtests as these scores 
already take age into account.
Subtests of the WAIS-R
The group means and standard deviations between patients and controls on 
subtests of the WAIS-R -  Block Design, Digit Span, Digit Symbol and Vocabulary - are 
presented in Table 5.
1  Clinically relevant levels are as follows for adult (non-student) samples: means of 0-7 (normal); 8-10 
(borderline); 11-21 (abnormal)Table 5: Group Means on Subtests of the WAIS -R
Group Block Design
Test
Digit Span Digit Symbol Vocabulary
Patients 9.14 10.22 8.85 11.51
(2.44) (2.59) (2.31) (1.45)
Controls 11.95 10.86 10.36 12.04
(2.68) (2.53) (2.08) (2.08)
F (1,45) =14.77* F(l,45) =1.84 F(l,45) = 4.61* F(l,45) = 54
* P<0.05
A MANCOVA was conducted to examine differences between the two groups 
(patients vs. controls), with the Anxiety and Depression variables (from the HADS) as 
covariates.  This found significant differences overall (F(l,48) = 4.04, P<0.05) that were 
due to poorer performance in patients on the Block Design test and the Digit Symbol 
test. This is presented in Figure 1.
Figure 1: Group Scores on Block Design and Digit Symbol Tests
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67Motor Speed
Table 6 shows group differences on tests of motor functioning: Task A and 
Speed determined from AMIPB Information Processing Speed Tests 
Table 6: Group Means on Tests of Motor Speed
Trail A
Test 
Task A Speed
Group
Patients 46.92 57.74 46.96
(13.21) (7.46) (7.28)
Controls 30.95 65.68 52.86
(6.41) (13.44) (9.80)
F(l,45)= 10.76* F(l,45) = 3.54 F(l,45) = 2.71
*P<0.01
A MANCOVA was used to analyse the data, using Age, Depression and Anxiety 
as Covariates. This found significant differences between groups on tests of motor 
functioning, (F(l,48) = 4.04, P<0.05). Further analysis showed group differences on the 
Trail A test
Memory -  Verbal and Spatial
Table 7 presents group differences between patients and controls on tests of 
verbal memory: Story IR = immediate recall of a prose, Story DR = delayed recall of the 
prose; LL1 -5 = list learning task and LLA6 = recall of items on list learning after a 
distraction
68Table 7: Group Means on Tests of Verbal Memory
Group Story -  IR
Test
Story -  DR LL 1-5 LLA6
Patients 34.59 30.14 35.59 8.29
(9.37) (9.18) (10.00) (2.64)
Controls 39.45 36.81 49.13 10.45
(12.07) (11.29) (7.55) (2.87)
F(l,45) = .16 F(l,45) = .28 F(l,45) = 15.72*  F(l,45) = 2.10
*P<0.05
A MANCOVA was used to analyze the data further in terms of performances on 
verbal memory tasks, with Age, Depression and Anxiety as covariates.
On tests of verbal memory, there was a significant difference on scores between 
groups overall (F(l,48) = 3.83, PO.05) overall. Further analyses revealed a significant 
difference between groups on the List Learning task (LL1 -5).
69Table 8: Group Means on Tests of Spatial Memory
Test
RCF-I  RCF-D  DL1-5  DA6
Group
Patients  84.33  78.52  32.74  7.18
(7.66)  (7.55)  (4.19)  (1.11)
Controls  86.68  84.22  35.59  7.50
(14.99)  (15.31)  (6.41)  (1.68)
A MANCOVA was used to investigate the data further, with age, anxiety and 
depression as covariates. This found no significant results, (F(l ,48) = .66, P>0.05).  The 
scores between patients and controls on the List Learning Verbal task and Design 
Learning Spatial Tasks are presented in Figure 2.
Figure 2: Mean scores between patients and controls on tests of verbal memory: List
Learning and Design Learning
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70Executive/Frontal Lobe function
Table 9 presents the scores between the patients and control groups on the tests 
of executive/frontal lobe function.
Table 9: Group Means on Tests of Executive/Frontal Lobe Function
Test
Group Trail B Stroop VF SF
Patients 89.03 101.18 31.70 20.00
(19.40) (7.03) (6.94) (6.30)
Controls 65.95 106.86 44.13 21.00
(20.11) (9.68) (11.03) (4.68)
F(l,45) = 9.99*  F(l,45) = 1.84 F(l,45) = 11.65* F(l,45) = .108
*P<0.01
A MANCOVA was used to analyse the data further, using Age, Depression and 
Anxiety as a covariates. This found that there were significant differences between 
groups on tests of executive/frontal lobe function, (F(l,48) = 4.67, P<0.05). Further 
analysis revealed group differences between patient and controls on the Verbal Fluency 
Test but not on the Semantic Fluency Test. This is presented in Figure 3.
71Figure 3: Mean scores between patients and controls on tests of frontal/executive
functions
g  45  - 
c  40  -
(A
&   30
□ Verbal Fluecy 
■ Semantic Fluency
o  25
patients controls
Group
There were also significant differences between groups on the Trail B test, with 
patients having slower performances than controls.
1.4.3  Summary -  Stage 1
Stage 1  involved comparing liver disease patients with a control group on 
performances on neuropsychological tests. On the domain of IQ functioning, there were 
significant differences between patients and controls on two tests that measured this - 
Block Design and Digit Symbol subtests. The patient group had significantly poorer 
performances on both and their age adjusted scaled scores were lower. There were no 
differences between patients and controls on other subtests of IQ functioning, namely 
Vocabulary and Digit Span, although on both tests patients again had lower age adjusted 
scaled scores.
On the domain of motor speed, significant differences between patients and 
controls were found on one test that measured this area of functioning - the Trail A test. 
Patients took longer to complete the task.  There were also significant differences
72between patients and controls on verbal memory -  the patients recalled fewer items on 
the List Learning task than controls. On spatial memory, no significant differences were 
found between patients and controls on tests that assessed this area of functioning.
Finally, on executive/frontal lobe function, there were again significant 
differences between patients and controls on some tests that assessed this area. Patients 
had poorer performance on die Verbal Fluency Test compared with controls. There were 
also differences between both groups on the Trail B test, with patients having slower 
reaction times.
The results therefore support the hypothesis that patients with liver disease have 
greater deficits in areas of cognitive functioning. They had poorer performances than 
controls on a wide range of neuropsychological tests, although a pattern of global 
cognitive deterioration was not observed.
1.4.4  Stage 2 -  Patients with liver disease
The next stage of the analysis involved investigating whether greater cognitve 
deficits were observed in those patients with more severe forms of liver disease and 
whether performance on neuropsychological tests was influenced by severity of disease, 
as determined by the Child Pugh scores.  Multiple analyses of variance comparing the 
three groups were conducted using the same grouping of variables as used in Stage 1.
Table 10 presents demographic information, premorbid IQ and information 
regarding severity of mood disorder amongst patients with different degrees of liver 
disease (determined by Child Pugh stage).
73Table 10: Group Characteristics Between Patients
Group Age Premorbid IQ HADS A HADS D
A 53.80 110.90 8.90 6.00
N= 10 (9.62) (6.87) (4.04) (2.30)
B 54.12 109.37 5.50 5.87
N = 8 (10.54) (2.61) (3.89) (5.16)
C 56.55 108.77 5.66 4.11
N = 9 (7.73) (8.05) (4.50) (2.52)
Separate one-way ANOVAs were performed to investigate differences between 
liver disease groups in terms of Age, NART IQ, HADS A and HADS D. No significant 
differences on any of the above variables were observed, although there was a non­
significant tendency for Group A to report more depressed symptomatology.
74Subtests of the WAIS-R
Table 11 presents differences between liver patients on the subtests of the WAIS- 
R - Digit Span, Vocabulary, Block Design and Digit Symbol; Groups A, B and C 
determined by Child Pugh score.
Table 11: Group Means on Tests of WAIS-R
Test
Group Digit Span Vocabulary Block Design Digit Symbol
A 11.50 11.80 10.50 9.60
(2.83) (1.75) (2.59) (2.01)
B 10.12 10.87 9.75 10.25
(2.03) (1.24) (2.12) (1.90)
C 8.88 11.77 7.11 6.77
(2.22) (1.20) (1.78) (1.48)
F(l,24) = 7.24 F(l,24) = 1.13 F(l,24) = 7.24* F(l,24) = 9.05*
*P<0.01
A MANOVA was performed on the data above to investigate group differences 
on the above tests.  This showed that there were significant differences between patients 
on these tests, (F(l,27) = 3.87, P<0.05). Further analyses revealed group differences on 
Block Design and Digit Symbol.
Independent samples t-tests were performed and the Bonferonni adjustment was 
set at 0.012. A significant difference was found between Groups A and C on scores of 
Block Design, (t(l 1) = 3.96, P<0.01) and on scores of Digit Symbol, (t(l 1) = 3.50, 
PO.Ol).
75Independent samples t tests also showed there were significant differences 
between Groups B and C on scores of Block Design, (t(l 1) = 3.48, P<0.01) and Digit 
Symbol, (t(l 1) = 4.21 ,P<0.01).
This is presented in Figure 4
Figure 4: Mean scores on subtests of WAIS-R: Block Design and Digit Symbol between
Groups A. B and C
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76Motor Speed
Table 12 presents differences between liver disease patients on tests of Motor Speed 
Table 12: Group Means on Tests of Motor Speed
Test
Group Trail A Task A Speed
A 41.50 61.90 48.10
(10.61) (4.22) (6.13)
B 44.25 57.50 49.12
(15.21) (9.42) (6.72)
C 55.33 53.33 43.77
(10.72) (6.30) (8.54)
A MANCOVA was used to investigate the data further. This found no significant 
differences between groups on tests of motor speed, (F(l,27) =1.88, P>0.05).
77Memory -  Verbal and Spatial
Table 13 presents the group means on tests of verbal memory.
Table 13 : Group Means on Tests of Verbal Memory
Test
Group Story-IR Story-DR LL 1-5 LLA6
A 30.30 26.30 40.50 8.20
(10.85) (10.87) (7.39) (3.04)
B 41.37 37.62 35.12 9.25
(12.07) (11.29) (7.55) (2.87)
C 33.33 27.77 30.55 7.55
(8.55) (7.04) (10.71) (2.29)
F(l,27) = 3.95*  F(l,27) = 5.01* F(l,27) = 2.64 F(l,27) = .87
*P<0.05
Separate MANCOVA’s were used to analyze group differences on tests of verbal 
memory and a significant difference was found between groups, (F(l ,27) = 2.53, 
P<0.05). Closer analyses revealed differences between groups on immediate recall and 
delayed recall of a story.  Independent t tests were used to investigate differences further 
and the Bonferonni adjustment was calculated at 0.012. These showed Group A had 
significantly worse recall scores than Group B on both immediate and delayed recall of a 
short story (t(l 1) = 3.06) and (t(l 1) = 3.10, P<0.012) respectively. This is shown in 
Figure 5.
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Independent t tests also showed that Group C had significantly worse scores on 
delayed recall of a story compared with Group B, (t(l 1) = 3.57, PO.012) but not on 
immediate recall of a story, t(l 1) = 2.62, P>0.012. This is shown in Figure 6
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Table 14 presents group differences on tests of spatial memory
Table 14: Group Differences on Tests of Spatial Memory
Test
RCF-I RCF-D DL1-5 DA6
Group
A 88.20 80.75 35.30 7.10
(7.98) (8.53) (4.39) (1.19)
B 85.00 79.25 31.37 7.00
(4.53) (6.51) (3.58) (1.30)
C 79.44 75.88 31.11 7.44
(7.43) (7.54) (3.33) (1.88)
No significant differences between groups were found on tests of spatial 
memory, (F(l,27) =1.51, PXX05)
80Executive/Frontal Lobe Function
Table 15 presents group differences on tests of executive/frontal lobe function
Table 15: Group Differences on Tests of Executive/Frontal Lobe Function
Tests
Group Trails B Stroop VFT SFT
A 74.90 102.80 33.50 21.11
(13.31) (7.95) (7.21) (4.85)
B 86.12 102.25 32.62 19.62
(14.98) (5.62) (7.57) (5.95)
C 107.33 98.44 28.88 19.22
(13.87) (7.03) (5.84) (8.21)
F(l,27) = 11.62* F(l,27) = .81
I
I
0
0
F(l,27)
*P<0.01
A MANCOVA found significant differences between groups on these tests, (F 
(1,27) = 2.23, P<0.05). Further analyses showed there were significant differences 
between groups on the Trails B test.
Independent t tests were performed to investigate group differences on the Trails 
B scores. These showed that Group C had significantly slower performances than Group 
A, (t (11) = .51, P<0.001) and Group B, (t(l 1) = .301, P<0.01). Scores were not 
significantly different between Group A and B, (t(l 1) = 1.68, P>0.05).
This is illustrated in Figure 7
81Figure 7: Mean RT (seconds) on Trail B Test between Groups A. B and C.
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1.4.5 Summary -  Stage 2
Stage 2 of the data analysis compared cognitive functioning in different liver 
disease groups, as determined by the Child Pugh Score.
On domains of IQ functioning, differences were observed. Group C had worse 
performances than Group A on die Block Design and Digit Symbol tasks. The findings 
also showed that performances were significantly worse in Group C on both of these 
tests than Group B. On tests of motor speed, Group C had worse performance on all 
three tests although the difference did not reach significance.
On domains of verbal memory, further differences were observed between liver 
disease groups. Group C had significantly worse performance than Group B on recalling 
a short prose after a delay. Additionally, Group A had poorer immediate and delayed
82recall scores compared with Group B. No significant differences were observed between 
liver disease groups on tests of spatial memory.
Finally on executive/frontal lobe function, differences were observed. Reaction 
times were significantly slower in Group C than Group B and A on the Trails B test.
1.4.6  Conclusion
The results from this study are mixed. Although they support both of the 
hypothesis tested, they show that there is also some variation. Therefore, there does not 
appear to be a global deterioration in cognitive deficits in liver disease (as measured by 
the neuropsychological tests used in this study).
1.5  Discussion
1.5.1  Overview
The findings support the hypothesis of deficits in cognitive functioning in 
patients with liver disease. Compared with controls, the liver disease patients had poorer 
performances on neuropsychological tests. The findings also support the hypothesis of 
greater deficits in those with more severe cases of liver disease. Those with more severe 
stages of liver disease (Child Pugh C) had worse performances on tests measuring 
cognitive domains than those with less severe liver functioning (Child Pugh A). 
Furthermore, the profile of deficit is similar to that seen between healthy control subjects 
and liver patients. The one anomaly was the observation that Group A had poorer 
performances than Group B on some domains (verbal memory) indicating memory 
deficits were experienced by those with better liver functioning.
In Stage 1 of the analysis, patients and controls were compared on 
neuropsychological performances on tests that measured cognitive domains and areas of 
functioning. General intellectual ability was relatively well preserved in the patient
83group. However, the results suggest they had greater impairment on most of the areas of 
functioning investigated; IQ functioning, motor functioning, verbal memory and 
executive/frontal lobe functioning. Their performances on tests that measured each 
domain were worse in all of these areas.
In Stage 2 of  the data analysis, patients with different severity of liver disease 
were investigated with regard to the same domains of cognitive functioning. The 
findings showed that those with worse stages of liver disease (the Child Pugh C Group) 
had greater deficits in some areas compared with those patients with less severe stages 
of liver disease (the Child Pugh A Group). Therefore, worse performances on various 
neuropsychological tests was observed when liver function was estimated to be worse 
and more severe; performances were shown to be poorer on domains of IQ functioning 
and some executive/frontal lobe tasks.
The results from the current study are therefore mixed. The first and second 
hypotheses were supported although there was not a global deterioration of deficits in 
patients with liver disease. Stage 1  and 2 found that performances by 1) liver disease 
patients and 2) more severe stages of liver disease were not consistently poor, i.e. on all 
neuropsychological tests.  An unexpected anomaly however, was that patients with 
better liver functioning in Group A had greater deficits in verbal memory functioning 
than those patients with worse liver functioning in Group B.
1.5.2  Comparison with previous research
The results from the current study tie in with previous studies that have found 
poorer performances on cognitive domains between liver disease patients and matched 
controls. Pantiga, Rodrigo, Cuesta, Lopez and Arias (2001) found that cirrhotic patients 
showed a degree of mental impairment in functions studied (memory and immediate
84recall, motor processing and mental flexibility and general reasoning/non-verbal 
intelligence). They argued that severity of the deficit was related to the degree of hepatic 
dysfunction. The current study partially supports this finding although it demonstrated 
deficits are not consistently observed in worse stages of liver disease. Those with better 
liver functioning demonstrated more impairment in verbal memory functioning. The 
current study differed also in that general reasoning ability was not directly studied.
Mechtcheriakov, Graziadei, Mattedi, Bodner, Kugener, Hinterhuber, Marksteiner 
and Vogel (2004) also found significant differences between patients with liver disease 
and controls on domains of motor functioning, executive functioning and memory. The 
current study therefore supports their work and reflects their findings.
Similar findings have been obtained by Weissenbom, Heidenreich, 
Giewekemeyer, Ruckert and Hecker (2003) who observed differences between patients 
with minimal hepatic encephalopathy and controls in domains of memory, attention and 
non-verbal intelligence.  However, they did not find consistent differences on memory 
functioning and spatial memory was preserved in patients with liver disease. This 
supports the findings from the present study in that no group differences on domains of 
spatial memory were observed in either Stage 1  or Stage 2 of the data analysis.
The most common patterns of cognitive deficit in patients with liver disease have 
therefore been observed in psychomotor and executive functioning. Other areas of 
ability are less well understood, for example patients have shown less prominent deficits 
in other neuropsychological domains, such as memory and verbal ability. Memory 
functioning has not been consistently demonstrated in patients with liver disease and 
some researchers have argued that deficits observed are primarily in attention and visual 
perception, rather than memory. The findings suggest that it is not the severity of liver
85disease that is associated with deficits in all areas of cognitive functioning and that those 
with less severe forms of liver disease can have deficits in verbal memory compared 
with those with more advanced liver disease.
In the present study, liver disease patients had worse performances on the 
domain of verbal memory than controls (as demonstrated by their scores on the list 
learning task). Spatial memory was not significantly worse in liver disease patients than 
controls, however.  This has been observed in other studies although findings with 
regard to spatial memory functioning in liver disease are mixed.
Verbal skills appear to remain intact in patients with liver disease and in the 
current study, patients did not perform worse than controls on verbal IQ, as reflected by 
the Vocabulary subtest of the WAIS-R. This has also been observed in other studies. For 
example, McCrea et al (1999) observed a selective dysfunction of attention and motor 
skills in cirrhotics in the absence of any impairment in general intellect, memory, 
language or visuo-spatial skills.
The findings do not suggest a global decline of cognitive functioning in liver 
disease. For example, it is apparent that significant deficits were not found between 
patients and controls on all tests used to measure motor processing. Although patients 
had worse performances on all tests that measure this domain, the differences did not 
emerge as significant on all tests. Likewise, a consistent pattern of deficits in 
executive/frontal lobe functioning was not observed in liver disease patients compared 
with controls.
The study differed from previous research in that few studies have directly 
compared performances between patients with different stages of liver disease, with 
severity determined by Child Pugh scores. Most studies have looked at performances
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Child Pugh stage C had deficits in IQ functioning than those with less severe stages of 
liver disease. Pantiga et al also found that patients with Child Pugh stage C had more 
impairment on frontal lobe/executive functioning skills than those with a Child Pugh 
score of A. The present study partially supports this finding in those patients in the Child 
Pugh C group had worse performances on one test that measured this domain (Trails B) 
compared with those patients in the Child Pugh B and A group. However, their 
performances on other tests did not differ significantly.
Another observation from the current research was that the liver patients had 
significantly higher means on measures of anxiety and depression the controls (although 
scores were not clinically relevant).  The psychological implications associated with 
liver disease have been studied to a lesser extent than cognitive deficits and could 
benefit from further research.
Severity of liver disease has been found to have effects on self-reported measures 
of well-being. For example, Park, Park, Kim, Park, Hyan, Yun, Jo, Tak, Kweon, Kim, 
Choi & Park (2003) found less severity of liver disease is associated with poorer scores 
on measures of mood. In the current study, those patients in the Child Pugh A group 
(less severe liver disease) had slightly higher means on the Hospital Anxiety and 
Depression Scale (Zigmond & Snaith, 1983) than those in the Child Pugh stage C group 
(more severe liver disease), although this did not reach clinical levels or significance and 
no conclusions can be drawn.
871.5.3  Emotional Factors
The present study found that differences between performances on 
neuropsychological tests were observed despite controlling for effects of anxiety and 
depression. Although the liver disease patients had higher means on measures of anxiety 
and depression than controls, these were not in the clinically relevant range. 
Additionally, statistical methods controlled for the effects of mood and the observed 
differences on neuropsychological tests between patients and controls cannot be 
attributed to effects of depression or anxiety. Therefore, this study found little evidence 
to substantiate the view that deficits were secondary to psychological distress.
Opinions differ as to the nature, extent and aetiology of cognitive impairment in 
depressed and anxious patients.  There may be other factors and variables associated 
with both mood states that may impact on functioning and performances (i.e. associated 
with quality of life, effort made and fatigue). It is also difficult to control for other 
potentially confounding variables such as medication.
Additionally, although some investigators have found differences between 
control subjects and depressed patients on certain memory (prose recall, list learning, 
design learning) and information-processing speed tasks (Watts, 1996) mood disorder is 
associated with a lesser degree of impairment than organic brain damage (Watts, 1996). 
Further still, differences in task performance between control subjects and those who are 
depressed have been shown to be non-existent or very small which has led some 
researchers to suggest that poor performance may be secondary to lack of motivation. 
Lezak (2004) for example found that depressed patients frequently show errors of 
omission or give ‘don’t know’ responses, suggesting a lack of effort.It can be suggested that the differences seen in the current study could be 
attributed to effects of state anxiety as opposed to higher but non-clinical levels of trait 
anxiety. A measure of state anxiety was not taken and patients could have been more 
temporarily anxious than control participants. Trait anxiety has been considered to have 
little effect on performance but state anxiety has opposing effects on high and low 
ability participants. It has been considered to enhance performance of high ability 
subjects but has the opposite effect on low ability subjects. In the current study, 
however, all participants were matched on premorbid IQ.
Physical fatigue, memory and concentration problems are reported by many liver 
disease patients. Chronic fatigue syndrome is the term usually applied to people with a 
history of unexplained fatigue coupled with other physical problems. It also includes 
people who are suffering from anxiety or depression and those with medical conditions 
such as multiple sclerosis. Although there is no specific abnormality associated with 
CFS, psychological disorder is found in approximately 75% of CFS patients. Around 50- 
70% of CFS patients complain of considerable difficulties with memory and 
concentration and these difficulties are often associated in occupational difficulties 
(McDonald, Cope & David, 1993). It is unknown how many patients in the current study 
were experiencing CFS.
Therefore, the current study suggests effects on neuropsychological 
performances cannot be attributed to psychological factors, such as anxiety or 
depression. However, this does not rule out such factors entirely, as effort and 
motivation might have been poorer in the patient group, or effects might have been a 
result of fatigue. For example, tests that require sustained attention and concentration 
(tests which measure memory functioning) or construction skills (some subtests of thewais, i.e. block design) or movement/psychomotor skills (tests such as Trails A) might 
be subject to fatigue.
Anxiety has been established in liver disease patients, particularly with regards to 
before and after liver transplantation (Moore, Burrows & Hardy, 2006). Patients with 
end-stage liver disease due to hepatitis C have also been found to be more depressed 
than other liver disease patients (Singh, Gayowski, Wagener & Marino, 1997). 
Psychological distress has also been observed in chronic, nonalcoholic, uncomplicated 
liver disease (Davis, De-Nour, Shouval & Melmed, 1998).
Collis & Lloyd (1992) discussed the effects of liver disease on mental health and 
explained how this topic has been relatively neglected in the literature. They discussed 
the psychological consequences of specific liver disorders including sexual function, 
mental disturbance, effects of childhood liver disease, psychiatric aspects of liver 
transplantation and the use of psychotropic drugs in patients with hepatic dysfunction. 
This implies there are a number of clinical implications and a role for psychological 
input with regards to the effective treatment and care strategies of patients with liver 
disease.
1.5.4  Implications of Cognitive Deficits
Most of the patients in the research reported having some difficulties with 
concentration and/or attention and although deficits were not consistently demonstrated 
on all aspects of functioning, some felt that they had experienced problems. Various 
implications arise from cognitive deficits. Poor psychomotor speed can lead to general 
slowing of reaction times and skills needed to make quick responses. This could impact 
on skills such as driving, operating machinery or attempting to perform various tasks at 
once. This could make eveiyday tasks, such as driving, difficult.As outlined earlier, Schomerus et al (2004) concluded that cerebral dysfunction 
in MHE had a major impact on patient’s daily living and concluded 60% of cirrhotic 
patients without clinical signs of HE were considered unfit to drive and in 25% driving 
capacity was questionable.
Additionally, Bajaj, Hafeezullah, Hoffman & Saeian (2006) discussed how MHE 
patients have impairment on driving tests although they explained how it remains 
unclear whether this impairment is restricted to testing or is associated with an increased 
risk of traffic violations.  They performed a study looking at 200 cirrhotics without overt 
HE and 100 age matched controls who were investigated with regards to a driving 
history and behaviour questionnaire inquiring about demographics, alcohol/illegal drug 
use and motor vehicle accidents and traffic violations within 5 years. Their results 
showed cirrhotics have a higher reported occurrence of both compared to controls. They 
also found that self-assessment of driving behaviour is not accurate in this population.
Poor memory would also impact on general functioning, especially verbal 
memory that relates to information heard and memory for words as opposed to memory 
for pictures. Therefore, deficits with verbal memory would manifest itself by 
impairments with remembering certain types of information, such as instructions or 
work-related activities.
1.5.5  Further research and implications
The literature on MHE has outlined how patients often describe mild cognitive 
alterations in this condition. It can be suggested that in some instances the changes are 
too mild to be acknowledged by the individual and can only be identified through 
objective tests. Or, alternatively, patients might feel they are lacking in concentration or 
have memory problems, yet objective tests might not demonstrate any deficits.
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between self report and objective measures between patients with different severity of 
liver disease.
Further research could also look into whether a specific ‘profile’ of cognitive 
deficits is characteristic of MHE. Although poor motor speed/executive functioning has 
been consistently demonstrated, other deficits could characterise this syndrome, such as 
memory impairments. The current study suggested verbal memory is associated with 
deficits in early stages of liver disease yet spatial memory is preserved. Therefore, 
further research could investigate this in order to see whether particular patterns of 
deficit emerge, such as in Attention Deficit Hyperactivity Disorder and Asperger’s.
Future research could help to establish features (i.e. cognitive deficits/the association 
between liver disease and mood) that are characteristic of various stages of liver disease. 
This could help identify those patients who display signs of minimal hepatic 
encephalopathy or early stages of liver disease and help establish ‘predictors’ of future 
problems.  This would enable early intervention and treatment strategies that would 
involve medical care and support of such individuals to reduce their symptoms, 
progression of liver disease and any further distress experienced.
Clinical considerations also emerge from this research. The types of deficits 
observed would clearly impact on a person’s life and ability to perform everyday 
activities. Reduced motor speed would manifest itself by a general ‘slowing down’ and 
an increase in time spent performing tasks. This could make simple tasks, such as 
climbing stairs or crossing a road, difficult and could ultimately affect a person’s safety. 
As outlined earlier, this could also impact of driving ability and increase the risk of 
accidents.
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implications. Executive functioning can be described as the brain's ability to absorb and 
interpret information and make decisions based upon such information. Deficits in this 
would include inappropriate interpretations, poor decision-making, loose associations, 
(thoughts loosely associated with one another), attention inhibition and impulsivity, 
problems shifting or switching attention, literal thinking and problem solving. It would 
also affect the ability to plan events successfully based on a set of instructions and 
devising various strategies, i.e. that would enable successful completion of a task.
Memory problems, specifically verbal memory difficulties would lead to increased 
forgetfulness of verbal material or for information heard. This would again impact on an 
individual’s everyday life as they would find it more and more difficult to remember 
instructions or information that they had been told. This would lead to difficulties 
keeping appointments or making arrangements. This could also affect personal safety, 
i.e., when using electrical appliances and remembering instructions for use.  Therefore, 
psychological input could involve helping patients manage and control these difficulties 
and helping them to develop strategies to compensate for their deficits.  For example, 
assisting with die development of strategies to aid memory (i.e. ‘post it’s’, diaries). 
Additionally, those with more severe stages of liver disease could benefit from extra 
support with performing everyday activities.
All of the above would have occupational consequences and it may be more 
difficult to keep a job. As outlined earlier, this was observed by Schomerus et al (2003), 
who found 73% of cirrhotics who were blue collar workers had impaired earning 
capacity in the presence of minimal HE; 50% of the white collar workers were fit for
93work, even in the presence of minimal HE due to the preservation of verbal abilities in 
this condition.
Further still, while 80% of white collar workers suffering from cirrhosis were 
considered fit for work, only 40% of blue-collar workers met such criteria. This 
illustrates the importance of a significant impairment of motor performance in minimal 
HE where verbal abilities appear unaffected. In relation to this, reduced work-related 
activities could lead to periods of unemployment, which could cause periods of anxiety 
(i.e. finance related) and depression (i.e. inactivity).
As quality of life has been reported as being poor in patients with liver disease, the 
implications in terms of mental health is also another clinical implication. Park, Park, 
Kim, Park, Hyan, Yun, Jo, Tak, Kweon, Kim, Choi and Park (2003) found quality of life 
scores were significantly lower in liver disease patients than controls and the differences 
were greater on measures of mental as opposed to physical health.  Additionally, when 
patient group was classified as Child A, B or C according to modified Child Pugh 
classification, severe liver disease was associated with lower quality of life scores. This 
suggests that quality of life decreases as liver disease worsens and could be correlated 
with cognitive deficits.  Therefore, determining a role for future psychological input due 
to poor outcome measures on mental domains is a consideration. For example, this 
might be most important for those patients in the severe stages of liver disease who have 
been found to report worse quality of life than those patients at less severe stages of liver 
disease.
1.5.6  Limitations of the research
The major weakness of the present study is the sample size. A total of 27 patients 
were included in the current study, making comparisons between patients and controls
94sufficient However, it is more difficult to make generalizations about the findings from 
the liver disease patients as numbers in each group were relatively smaller. The largest 
group was the Child Pugh A group, which contained 10 patients. However, Group B had 
8 patients and Group C 9 patients. Therefore, it is important to bear this in mind when 
attempting to make generalizations about the wider liver disease population.
Another limitation is that only one psychological measure was included in the 
present study and the research would have been improved if another measure was 
included, i.e. of general wellbeing. This might have shed light on why the patients in the 
study reported higher anxiety and depression scores, (although these were not clinically 
significant), than the control group. A wider understanding of their experiences might 
have been derived.
A further weakness is that patients with liver disease of different aetiologies were 
included and it is therefore not possible to make conclusions about cognitive deficits 
observed in specific types of liver disease. However, this has been acknowledged in the 
literature and further work will help establish whether there are precise ‘patterns’ of 
cognitive deficits associated in various types of liver disease.
The current study did not include any of the tests that have been used in some 
clinical and research settings for diagnostic purposes with regards to minimal hepatic 
encephalopathy. Patients did not participate if they were thought to have overt signs of 
hepatic encephalopathy. However, due to the complexities associated with the 
measurement of minimal hepatic encephalopathy, no definite conclusions about 
cognitive impairments in this syndrome can be drawn although findings can be 
considered in further research into this syndrome.  A further elaboration of findings, 
with ideas for future research and clinical implications is given in section 3.
951.5.7  Conclusion
The results from the current study therefore suggest possible deficits in liver 
disease in terms of psychomotor speed and frontal/executive functioning. They also 
suggest that different patterns of deficits emerge in different severity/stages of liver 
disease. The research has therefore provided a basis that can be followed up in future 
studies in order to understand the patterns and nature of deficits in patients with liver 
disease.
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103Part 3:
Critical Appraisal1.1  Personal reflection.
The research reported in this thesis has been both an interesting and challenging 
experience. At times the process was rewarding, at others very frustrating. Research is 
central to the role of a clinical psychologist as it enables further knowledge of 
psychological problems. The current research constituted a complex study into a medical 
condition. It involved considering studies from different areas and incorporating both the 
medical model with psychological theories. Although this was an interesting and 
innovative way of understanding the impacts of a medical condition, the approach did 
have its challenges.
Liver disease is a complex physical illness and the prevalence is increasing. The 
incidence of excessive or ‘binge drinking’ is also increasing. The long time implications 
of this are unknown but substantial research has shown increased alcohol intake 
increases chances of developing liver disease, which is associated with cognitive, 
behavioural and physical problems. Also, the prevalence of mental illness in liver 
disease has been questioned and the impact on quality of life, ability to perform 
activities in general living, maintain employment/social life, capacity to manage 
finances, drive and maintain self-care, etc, is poorly understood.
Collis and Lloyd (1992) outlined how the effects of liver disease on mental 
health are relatively unknown and that this is a topic that been neglected in recent 
psychiatric literature. In their review, they outline how further work should address the 
psychological consequences of specific liver disorders, including sexual function, the 
relationship between alcohol and hepatic disorder in causing mental disturbance, the 
effects of childhood liver disease, psychiatric aspects of liver transplantation and the use 
of  psychotropic drugs in patients with hepatic dysfunction.
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something that is also central to the role of a clinical psychologist. This provides an 
insight into the many different aspects of an individual’s problem. The patients whom 
participated in the research were attending a specialised hepatology clinic as part of their 
medical care. The hypothesis that was addressed was that such patients would have 
cognitive deficits as demonstrated on neuropsychological tests. Previous work had 
shown patients complained of cognitive alterations and reduced work-related activities. 
However, due to lack of research, the precise spectrum of deficits and their cause 
remained unknown.
1.2  Why choose a Neuropsychological study?
The study of the various brain regions and how they are involved in cognition is 
a very interesting area of psychology and can be used to understand both normal and 
impaired processes. The reasons for choosing a research study can be both influenced by 
practicalities (i.e. constraints of work/placement settings) and personal (i.e. interests and 
motivation). As the research reported was not influenced by placement constraints, the 
main reasons for choosing the study were personal interest.
Before starting the Doctorate in Clinical Psychology in 2004,1 had completed a 
Ph.D. in attentional biases in anxiety. Therefore, I had a keen interest in psychological 
factors in mood states, how particular thought styles and patterns develop and how they 
are maintained. Although I enjoyed the Ph.D. experience, the research mainly involved 
studying undergraduates and I found that any findings were difficult to generalise to the 
general population. I also developed an interest in researching clinical populations as I 
personally found this more fulfilling.
106Although I would have liked to extend the findings from my Ph.D. to clinical 
populations as part of the research whilst on the course, this was not possible to do 
practically.  Therefore, I decided to follow a research project in another area that I was 
very interested in which was Neuropsychology. I had enjoyed this in my undergraduate 
degree although I had little experience of neuropsychological testing.  I also was very 
keen to further my experience in this area and thought the research would provide a 
unique opportunity to discover whether it is an area I would like to work in upon 
finishing the doctorate at UCL.
At the time of choosing a suitable project for the thesis, it became apparent that 
there was an opportunity to work in collaboration with the Institute of Hepatology (IoH), 
University College London.  There were a few possible projects to follow, so a meeting 
followed with the consultant of Hepatology and his Research Fellow. At this stage, the 
Research Fellow was very keen to have some extra psychological input on a study he 
was carrying out looking at the effects of probiotics. However, this study sounded much 
grounded in the medical model and I decided against becoming involved. I was given 
some references from both my internal and potential external supervisors (the 
Hepatology consultant at the IoH).
Choosing a viable and realistic research project that was suitable for a trainee 
clinical psychologist proved difficult; the references were rather complex and contained 
a lot of medical terminology. At times, it felt rather overwhelming and the literature 
extremely complex.  Consequently, it could feel impossible to conduct a project that 
would be suitable for a DClinPsych project -  some of the ideas sounded as if they were 
beyond the scope of a suitable project because of time and resources that would be 
required to undertake the work.
107I eventually decided on investigating the characterisation of cognitive deficits in 
liver disease. As outlined above, I was keen to further my experience of 
neuropsychological testing and found this option the most realistic.
1.3  Planning of the Research
One of the biggest challenges was actually coming up with some clear aims and 
objectives for the study. At the early stages of this process I often felt rather unsure of 
any specific aims and rather overwhelmed with the literature and the medical 
terminology.
Minimal Hepatic Encephalopathy is still a relatively new phenomenon and little 
is understood about the psychological effects on people with early stages of liver disease 
(Pantiga et al, 2001). It is understood of manifesting itself by subtle cognitive changes 
and reported cognitive alterations (Matorrozi et al 2007), with reduced work related 
activities. Although there appeared to be some scope for psychological input, it was not 
altogether clear about what this input could be.  There had to be a justification for 
performing neuropsychological tests on people who were in poor health and comparing 
them to a control group and it took some time to arrive at this, as well as a suitable 
study.
Subsequently, the initial proposal was heavily questioned and required major 
amendments. There was some confusion about aims, methodology and design. The 
proposal was generally considered to be vague and unspecific, which probably reflected 
the complexities of the area and the lack of clarity felt. Therefore, the proposal was 
revised and upon further reading of possible effects of MHE, it was decided to use the 
increased ammonia hypothesis as a basis for making specific hypothesis about what was 
expected to happen in the research, i.e. as the severity of liver disease increases possibly
108due to increased ammonia levels, cognitive deficits would become increasingly 
impaired.
In retrospect, it would have been useful to have had more time to read and 
understand the literature but due to tight deadlines this was not possible. Fully absorbing 
the literature in order to arrive at a suitable and appropriate study was time consuming 
and the study could be considered a little ambitious for a trainee, given that a design was 
not already available. It would have also been useful to have had a series of meetings 
scheduled in between my internal and external supervisors as at times it felt difficult 
juggling the demands and requirements/points of view from different directions.
Once the revised proposal was approved, it was necessary to think about ethical 
approval and constructing participant information sheets. It was also necessary to 
consider a test protocol and familiarize myself with neuropsychological tests. All stages, 
again, were associated with many challenges and it took some time to address. 
Consequently, I felt rather behind and my general progress was questioned regularly.
1.4 Methodological issues
Once a general aim with specific hypothesis had been achieved, it was necessary 
to think about the design and test protocol, as outlined above. The design of the study 
appeared quite straightforward and the test protocol involved deciding on a test battery 
to include in the study. All tests used were well validated, researched and standardised. 
Having little experience of neuropsychological testing, this part was decided on by my 
internal UCL supervisor and decisions about which tests were reached after reviewing 
other studies that had found cognitive deficits in early stages of liver disease. A full, 
comprehensive test battery was decided on in order to consider the full spectrum of 
possible deficits in this patient group.
109There were a number of further, ethical considerations to consider in the study. 
One was the testing of patients who were clearly unwell, especially those in the ‘later’ 
stages of severity of Liver Disease as measured by the Child Pugh C group.  Therefore, 
informed consent was always given and the full purpose of the study explained. Patients 
were also compensated for their time. However, as the study progressed it was clear that 
most patients were happy to help out and felt that they were giving something back to 
the doctors who had helped them. They felt that they wanted to be involved in research 
that would further knowledge and understanding about their condition.
Although most patients were keen to oblige, and understood about having little 
direct benefit by participating in the study, one or two patients were clearly confused 
about the reasons they were asked. For example, one worried about whether or not the 
study was identifying patients with dementia. Other complications included lack of 
understanding about my role and one patient appeared frustrated that I did not have a 
wide understanding of his condition and had not read his file. Therefore, these could be 
issues that might lead to questions about the ethical stance of using patients who were in 
poor health to participate in a study such as this.
Patient recruitment was another challenge associated with the research. A copy 
of the research proposal was sent to my external supervisor at the IoH/UCLH and his 
registrar. This included inclusion/exclusion criteria with regard to the suitability of 
patients who could participate. The registrar was to send names and hospital numbers of 
such patients and it was my duty to contact the secretary for contact details. However, it 
soon became apparent that some patients had been selected who were not suitable for the 
study. For example, some had ongoing alcohol use and a couple were clearly
110intoxicated. Further still, patients would at times not attend nor cancel their 
appointments.
Further challenges with regard to recruitment included having to contact the 
secretary at the clinic for contact details of all foe patients I was sent (foe process could 
take up to two weeks for each patient) and having very ‘dry’ periods when no patients 
were sent The registrar left half way through foe study and other members of the 
medical team at UCH were left with the responsibility to send patients to me for foe 
study. However, this involved having to constantly ‘chase’ foe medics involved which 
could be difficult to implement.
Moreover, further difficulties were encountered with regard to the actual testing 
of patients. There was not always a room available at foe liver clinic (where I would 
meet patients) so one needed to be booked through foe reservations system. The room 
offered could be at one of numerous locations and sometimes it involved a short walk 
from foe hospital. At times, patients would turn up with mobility problems and this was 
difficult. At other times, patients would simply not show up or cancel their 
appointments, or turn up with partners who were very keen to sit in on foe sessions.
Further still, as I required foe patients Child Pugh scores in order to determine 
which group each patient would be allocated to, (i.e. 10 in each group) it was necessary 
to keep track of the patients I had seen. This was another challenge as foe scores of 
patients I saw were not known at foe time of testing and I needed to find them out 
afterwards. This needed to be forwarded to me by a medic and was again, very time 
consuming. It would have been helpful to know foe score prior to testing foe patients and 
this is a consideration for further research.
IllAdditionally, with regard to the actual testing sessions, this was fairly long and it 
felt uncomfortable at times asking patients to complete tasks when they had difficulties. 
Some grew frustrated and others often wanted to talk about medical complaints or take 
the opportunity to discuss their personal problems.
Such issues reflect the complexities of performing research in National Health 
Settings and relying on various team members who are already exceptionally busy and 
under many demands. As my study did not directly involve such team members, they 
were still expected to help out and assist and this at time felt difficult to manage. To 
overcome such difficulties, future studies should perhaps not be carried out unless all 
staff members are informed of the necessary work involved and are asked about whether 
they will be able to assist as required. At time sit could feel very daunting when things 
had not been done and I could feel quite unsupported.
Therefore, various difficulties were encountered with regard to the entire 
recruitment process. Although this was frustrating at times, I felt the experience helped 
to develop particular skills such as having to be very well organised, determined and 
fairly resilient when encountering problems. It was necessary to constantly think in 
advance and ‘chase’ things. I found it important to keep up to date with other work that 
was not beyond my control, such as getting on with written aspects of the thesis. 
However, I was testing patients more or less up until the deadline of thesis submission 
and with other demands to meet (new placements, preparing case reports and 
submission) it was a stressful period.
Nevertheless, I have found the experience worthwhile. I feel that the findings 
have helped to contribute to some further understanding about liver disease, an 
important medical condition that affects many people everyday.  I feel the research will
112be able to help further knowledge and understanding about the impact of early stages of 
liver disease.
I initially felt that MHE was a rather controversial and vague phenomenon. 
Although I have a clearer understanding of it, i.e. what possible cognitive deficits are 
and how they might be caused, I remain feeling that there is further scope for more 
research. For example, there remains no uniform measure of it or diagnostic tool. The 
medical complications of MHE remain complex to someone who has studied 
psychology.
2.0  Expansion of discussion
2.1  Findings
A key finding from the current research was that cognitive deficits in liver 
disease were not accounted for by emotional factors. It suggests that medical/biological 
models might provide an explanation of deficits in liver disease as opposed to 
psychological ones. Deficits on domains of cognitive functioning were observed; 
patients were significantly worse on tests of executive functioning, psychomotor 
performance and verbal memory tests compared with controls. Additionally, cognitive 
functioning was poorer in more severe cases of liver disease. Although a global pattern 
of cognitive deterioration/functioning was not observed in patients with liver disease, the 
findings suggest a biological process associated with the disease might explain declines 
in cognitive functioning.
The finding of cognitive deficits independent of mood supports the work by 
Forton, Thomas, Muiphy, Allsop, Foster, Main, Wesnes and Taylor-Robinson (2003). 
They found that patients with mild hepatitis C had impairments on concentration and 
speed of working memory, yet were not significantly or clinically more depressed than
113controls. Although the current study differed with regards to type of cognitive 
impairment observed, it also suggests that deficits were unaccounted for by depression, 
suggesting a biological/pathological process in liver disease underlies the abnormality or 
types of deficits observed.
2.2 Mood and cognitive functioning
Much research has demonstrated the impact of mood on cognition.  For example, 
a common finding is the role of attentional biases in trait and state anxiety, with biases in 
selective attention (Mogg & Bradley, 1999; Williams, Watts & MacLeod, 1997). Stroop 
studies have shown that people with generalised anxiety have a poorer performance on 
Stroop tests when required to read out lists of threatening words and this has been 
interpreted as a bias in selective attention (Mogg & Bradley, 1998). Hyper vigilance has 
also been widely demonstrated in anxiety (Eysenck, 1992; 1997).  The current research 
does not suggest a role for emotional factors in cognitive functioning in patients with 
liver disease although this is an issue which would benefit from further research.
2.3 Causes of Deficits
The current study has made a significant contribution to the study of cognitive 
functioning in liver disease. It has suggested that psychological factors may not be 
clearly associated with cognitive impairments observed in those with liver disease. The 
precise causes of cognitive deficits observed in MHE remain unknown. The current 
study suggests causes stem from biological as opposed to psychological factors. As 
discussed, they might result from pathogenic processes similar to that occurring in overt 
HE, but at a milder level. That is, these diseases might directly affect brain function, 
resulting in cognitive impairment (Collie, 2005).  The present study suggests this
114impairment might be attributed to frontal lobe damage, which is involved in motor 
functioning.
Other research has been used to offer an explanation of which brain regions might 
be affected in liver disease patients to account for cognitive deficits. O’Carroll, Hayes, 
Ebmeier, Dougall, Muray, Best, Bouchier & Goodwin (1991) found significant overall 
impairment in cirrhotic patients compared with controls and regional cerebral blood flow 
was measured. The degree of cognitive impairment was directly correlated with 
functional abnormalities in the basal ganglia and limbic cortex.
Increased ammonia levels (as outlined earlier) might be one possible explanation. 
However, other hypotheses have been proposed, such as increased neurotransmitters that 
are found in various brain regions in excessive quantities, such as increased GAB  A.
2.4  Future Research and Clinical Implications.
A number of research and clinical implications have arisen from the current 
research. Further studies can help establish some of the biological causes of liver disease 
with regards to various toxic substances or pathways involved. They can also help 
establish types of cognitive deficits in various stages and severity of liver disease. 
Additionally, future studies could be performed which overcome some of the limitations 
associated with the current one.  For example, one important consideration is that the 
current study did not account for effects of effort or fatigue.  It can be suggested that the 
patients had a poorer performance on neuropsychological tests as they simply lacked in 
effort.
Fatigue is also important to consider. Swain (2000) discusses how this is a distressing 
and very common symptom in chronic disease. However, because of the subjective 
nature of fatigue, and the lack of effective therapeutics to treat it, the symptom been
115ignored by clinicians (Swain, 2000). Recently, fatigue has received greater attention as 
part of overall health related quality of life assessments in patients with chronic disease. 
In the current study, fatigue might have played a role when performing tests of motor 
functioning, for example.  Further research could attempt to control for effects of fatigue 
and effort in order to understand how this may present clinically.
Further research could also look into the type of factors necessary to enable a decent 
quality of life. As outlined earlier, patients with liver disease have tended to report 
poorer quality of life status than controls, and the precise reasons for this remain 
unknown. Studies have tended to illustrate family factors and support networks, yet few 
have been performed and a wider understanding of some of these factors is required. It is 
also unknown as to whether disease severity is associated with quality of life as few 
studies on this have yielded mixed results.
The implications of abdominal pain in liver disease could be further investigated. As 
outlined earlier, many people with chronic hepatitis experience abdominal pain or 
discomfort around their liver. Although this has been attributed to many causes (Palmer, 
2004) the full consequences of this in terms of cognitive deficits or wellbeing could be 
investigated further. It can be suggested that if one is in pain, it could impact on both 
domains either directly or indirectly (i.e. through fatigue or effort).
Indexes of quality of life specific for MHE have not been developed and exactly 
which aspects of life are affected in the condition is unknown. There are also different 
therapeutic alternatives for MHE. Improvement in neuropsychological tests has been 
reported with vegetable protein diets, for example. Those therapies that are active for 
overt hepatic encephalopathy are also considered valid for MHE. However, another 
critical question is whether specific therapies should be tailored to suit the individual,
116depending on their major individual difficulties.  This could involve predominantly low 
mood, anxieties, cognitive dysfunctions or poor perceived quality of life, etc.
2.5  Strengths and weaknesses
A number of strengths and weaknesses can be identified with the research. Key 
strengths are that it has provided an understanding of some of the effects liver disease 
might have on cognitive functioning and the various difficulties people may experience. 
It has therefore also been a worthwhile and innovative piece of work that can be built 
upon and developed.
A strength lies in the actual methodology and design. Patients with various stages of 
liver disease were assessed using a comprehensive neuropsychological test battery and 
performances on all aspects of neuropsychological functioning were compared. All 
neuropsychological tests used were well validated and standardised tests that have been 
widely used in research settings.  Additionally, the study incorporated both a between 
subjects and within subjects design.
A further strength was that additional measures were taken that were concerned with 
other aspects of psychological functioning and wellbeing. Again, the Hospital Anxiety 
and Depression Scale is another well respected measure. Therefore, there is plenty of 
scope to follow up various ideas that has emerged from the research. Few studies, if any 
have taken such psychological measures so effects of anxiety and depression might have 
occurred and impacted on test performances.
Although the research can be viewed as a thorough and extensive study, a number 
of weaknesses can also be identified. The main weakness could be the use of 
neuropsychological tests to determine functioning or ability. Various confounding 
factors might have influenced test performance, such as effort and fatigue. Some patients
117did not have English as a first language (although were considered fluent in English and 
appropriate for the study), so various cultural differences might have impacted on their 
performance. Therefore, future research could consider ways of controlling for this.
A further limitation with the research investigating cognitive functioning in 
hepatic encephalopathy is that different researchers have used different tests to assess 
areas of functioning. This makes it difficult to make sensible conclusions about findings 
and has been acknowledged in the literature.
Another weakness is the small sample with regards to the within subjects (i.e. 
different patient groups/severity of liver disease) comparisons. In order to make 
generalisations, more patients could be tested.
Further still, a limitation with the current study was that a measure of overall 
wellbeing/quality of life was not included and this could be included in future research 
to gain an understanding of general quality of life. Therefore, future studies should 
include a measure of this as, although in the current study patients’ performances cannot 
be attributed to either anxiety or depression, other forms of psychological distress might 
have impacted on their performances yet this was not detected through any particular 
measure used in the study.
2.6  Summary
In summary, a number of clinical and scientific implications have emerged from 
this research. Clinically, it is useful to consider deficits patients with liver disease might 
have and why this might be the case.  If patients are experiencing significant cognitive 
and/or psychological problems, they could be offered various forms of psychological 
input. For example, if they are having significant memory impairments or
118attention/concentration deficits, they could be taught how to use various strategies or 
techniques to compensate for this.
The research has also contributed to the understanding of the relationship 
between severity of liver disease and cognitive impairment, with possible explanations 
of how progression of liver disease might exert effects on functioning.
Further research could also be carried out in order to help determine the extent of 
cognitive deficits. For example, further studies could use a larger sample size in order to 
investigate whether observed effects remain. Additionally, effects of fatigue and effort 
could be controlled for in order to see whether effects remain. Further still, additional 
measures of quality of life could be used in order to assess whether certain difficulties 
are commonly reported in various stages of cirrhosis.
Therefore, various inputs from a psychological perspective could be developed in 
order to answer remaining clinical and scientific issues that have emerged through the 
current study.
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121AppendicesAppendix A: Letter of Ethical ApprovalROYAL FREE AND UNIVERSITY COLLEGE 
MEDICAL SCHOOL
DIVISION OF MEDICINE
THE UCL INSTITUTE OF HEPATOLOGY
11™ SEPTEMBER 2006
Dear  ,
REC ref N°:   
REC name: Committee A
Study Title: A study to assess whether driving hazard perception is impaired in chronic liver 
disease.
Further  to  the  telephone  conversation  I  had  with  your  colleague,  Asha  today,  below  I  outline  the 
neuropsychological  test  battery we will  ask our study volunteers to perform.  As discussed,  this is a 
minor  amendment  to  incorporate  a  few  standardised  tests  which  will  only  involve  a  clinical 
interview/questionnaire to cover self-reported  levels of functioning.  The test battery will now take  1  
hour rather than the 20 minutes (as previously stated in our earlier ethics submission for just the hazard 
perception  test).  Therefore,  in  addition  to  the  hazard  perception  test,  we  wish  to  now  include the 
following standard neuropsychometric test battery as our neuropsychological outcome measures;
Psychological measures
•  Beck Anxiety Inventory
•  Beck Depression Inventory
Quality o  f li  fe
•  Sickness Impact Profile
Premorbid Ability and current ability:
•  Wechsler test of Adult Reading (WTAR) National Adult Reading Test (NART)/WAIS R
Memory:
Recall and recognition:
•  AMIPB (list, story, design, figure, immediate delay, recognition)
Frontal regions:
This will be assessed by the Verbal Fluency (FAS) test and Stroop (subtests from the WAIS)
Motor:
Digit Symbol; Trails A & B, AMIPB (story and figure tests)
If any further information is required please do not hesitate in contacting me to discuss this matter or 
request further information.
Yours sincerely,
Clinical research fellow (to Dr  )Appendix B: Information Sheet and Consent FormAppendix 2
CONFIDENTIAL
Patient Information Sheet
CIRRHOSIS STUDY
You are being invited to take part in a research study being carried out by a research 
team from University College London (UCL) and The Institute of Hepatology (IoH). Before you 
decide it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and ask us if there is 
anything that is not clear or if you would like more information.
Purpose of the study
The main aim of the study is to assess the impact of cirrhosis on overall wellbeing 
including general mood and quality of life and their abilities to perform certain tasks.
Background
In patients with cirrhosis of the liver, the toxin ammonia which is normally removed by 
the  liver,  builds  up.  Excess  ammonia  is  associated  with  a  condition  called  Hepatic 
Encephalopathy. This is associated with a variety of symptoms and often patients with chronic 
liver disease suffer from a mild but persistent form of Hepatic Encephalopathy. This can reduce 
the quality of their lives, impairing concentration and their ability to drive as safely as a patient 
without chronic liver disease.
The Driving Standards Authority (DSA) requires anyone taking a driving test in the 
United  Kingdom  to pass  a  theory  test  in  additional  to  die  practical  component.  From  14 
November 2002, the theory test has also included a test of hazard perception skills. The hazard 
perception element consists of 14 video clips, which feature real road scenes and developing 
hazards of various types, such as vehicles and pedestrians. To pass the hazard perception test, an 
individual must score 50%.
Therefore, we are also interested in assessing whether patients with liver disease find 
this test harder and score less well than people who do not suffer from liver disease. This will 
help us to assess what percentage of patients with liver disease may be affected by Minimal 
Hepatic Encephalopathy.
Why have I been chosen?
We are interested in assessing the range, nature and extent of possible deficits in patients 
with different levels of cirrhosis to determine the extent to which  it affects everyday  fives. 
Therefore, we have been asking those individuals who are known patients with cirrhosis.
What does the study involve?
You will take part in a clinical  assessment and clinical interview.  The assessment 
involves pen-and-paper tests of information processing, including memory and attention.  Theinterview will ask about your work history, quality of life and psychological wellbeing. You will 
also be asked to fill in some questionnaires about these aspects of your lives. You will then be 
asked to undertake a computer based test designed to recreate the hazard perception element of 
the modem driving test. A low score on this test in no way implies you are a bad or unsafe driver 
or have failed a driving test. We use the result to give us specific information on attention and 
perception for research purposes only. You do not need to contact the DVLA as a result of this 
test and the result will not be passed onto any third party or the DVLA.
The appointment will last approximately 1  hour and 30 minutes, (although this might 
take longer if you require breaks during the session). We will also require information about the 
severity of cirrhosis, as diagnosed by your consultant.
Expenses
We are able to reimburse any travel expenses incurred by your participation in this study.
Will I be able to see the results of the study and what are the benefits of taking part?
Feedback will be given after the assessment. The results of the study will contribute to 
the understanding of cirrhosis and help in the development of future treatment strategies and 
overall support of patients.
What if there is a problem?
Any complaint about the way you have been dealt with in the study or any possible harm 
you  might  suffer  will  be  addressed.  Please  contact  the  principle  investigators,  Dr  Sarah 
Mackenzie-Ross ( ) or Dr Oliver Mason ( ).
You must understand that you are under no obligation to participate in this study and if 
you  are  unwilling  to  participate  in  this  study,  then  it  will  in no  way  affect  your  further 
management. If during the course of the study you do not want us to continue with the study, we 
will stop the study at that instant. This study is being performed under the supervision of Dr R 
Jalan ( ), Dr Sarah Ross ( ) and Dr Oliver Mason ( ). If 
there are any questions with regard to this study you can speak with him at any stage. Dr S 
 (Consultant Physician, Middlesex Hospital, Mortimer Street,  ), who is a 
consultant physician not directly involved with this study, shall be happy to provide independent 
advice.  We  can  also  assure  you  that  all  the  data  acquired  from  your  study  will  be  kept 
confidential in keeping with The Data Protection Act.CONFIDENTIAL 
PATIENT CONSENT FOR CIRRHOSIS STUDY
Name of patient 
DOB
Hosp. Number
----------------------------------   (YES/NO)
Have you read the information sheet?...........................................................
Have you had the opportunity to ask questions?  ...............
Have you received satisfactory answers to your questions?  ...............
Have you received enough information about the study?............................
I understand that this is non-therapeutic research from which 
I cannot expect to derive any benefit.............................................................
Do you understand that you are free to withdraw from the study:
At any time..........................................................................................
Without any reason  ...............
Without affecting your future care  ...............
Do you agree to take part in the study  ...................
Signature of patient  Signature of investigator
Date........................
(For information contact Dr  )
3 copies to be made:
Top copy to be retained by Investigator 
Second copy to be retained by patient 
Third copy to be filed in hospital notes